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1. Introduction
Some clinical views which appear during hyperthyroidism can be called complications of
hyperthyroidism. These clinical events are as follows.
1. Thyrotoxic heart disease
2. Progressive infiltrative ophtalmopathy in hyperthyroidism
3. Hyperthyroidism and bone
4. Thyroid chrisis
5. Thyrotoxic periodic paralysis
6. Thyrotoxicosis related psychosis and convulsion
7. Thyrotoxicosis related diabetes mellitus
2. Thyrotoxic heart disease
2.1. Effects of hyperthyroidism on heart-from pathophysiology to clinical complications
Cardiovascular signs and complications are generally the first alarming signs of hyperthyr‐
oidism for any physician. Effects of thyroid hormones on the heart and cardiovascular system
could be direct or indirect. Palpitations and exercise intolerance are the most frequent signs [1,
2]. Although effects of iodization and world-wide use of radiocontrast agents may change the
incidence, overt hyperthyroidism is common and affects 2-5% of the population [3,4]. In
hyperthyroid patients mortality is increased 20% and the major causes of death are cardiac
problems [5]. Atrial fibrillation is the most common and fearful arrythmic complication of
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hyperthyroidism which occurs in an estimated 10-25% of all overtly hyperthyroid patients [6].
Susceptibility to arrhythmic effects of thyroid hormones may have a genetic basis and recently
the studies on molecular details of cardiac actions of thyroid hormones revealed some
important knowledge [7]. Meanwhile, the cause of hyperthyroidism may also change the
cardiovascular risk; patients with toxic multinoduler goitre have higher cardiovascular risk
than patients with Graves’ disease, probably because of older age, and patients with Graves
disease may have autoimmune complications, such as valvular involvement, cardiomyopathy
and pulmonary arterial hypertension [8]. Effects of thyroid hormones on the heart may be
grouped as molecular or cellular mechanisms and hemodynamic effects. On the other hand,
thyroid hormones have 2 types of effects on every tissue; genomic effects which occur more
slowly, and non-genomic effects. Severity of hyperthyroidism may also cause differences in
clinical presentation of the patient, overt hyperthyroidism and subclinical hyperthyroidism
bring differing degrees of risks to patients.
2.2. Molecular and cellular mechanisms of thyroid hormone effects on heart
Both  T3  and  T4  are  lipophylic  and  they  pass  through  the  cellular  membranes  and  the
conversion of  T4  to  T3  occurs  in  many cells.  Triiodothyronin  (T3)  is  the  active  thyroid
hormone and it has genetic and cellular effects on cardiac muscle and blood vessels. It acts
on THRs (thyroid hormone receptors) in the nucleus, creating dimers of 9-cis-retinoic acid
receptor (RXR) (9): the formed complexes recognize some specific DNA consensus sequen‐
ces, the thyroid response elements (TRE), located in the enhanced region of the genes initiate
the transcription [9].
In myocytes, thyroid hormones act on many TREs, such as alpha myosin heavy chain fusion
(MHC-α), sarcoplasmic reticulum calcium-activated ATPase (SERCA), the cellular membrane
Na-K pump (Na-K ATPase), β1 adrenergic receptor, cardiac troponin I, atrial natriuretic
peptide (ANP) [10-12] and some genes are also suppressed such as β-myosin heavy chain
fusion (MHC-β), adenylic cyclase (IV and V) and the Na-Ca antiporter [13].
Thyroid hormone upregulates α, but downregulates β-chain in myocytes [14]. The final effect
of thyroid hormones in animal studies is an increased rate of V1 isoform of MHC (MHCα/α)
synthesis that is characteristically faster in myocardial fibre shortening [13,15]. A similar effect
has been also observed in preliminary human studies [16,17].
Thyroid hormones also have effects on SERCA, which is responsible for the rate of calcium
uptake during diastole, by actions on calcium activated ATPase and its inhibitory cofactor
phospholamban [18,19]. Thyroid hormones enhance myocardial relaxation by upregulating
expression of SERCA, and downregulating expression of phospholamban. The greater
reduction in cytoplasmic calcium concentration at the end of the diastole increases the
magnitude of systolic transient of calcium and augments its ability for activation of actin-
myosin subunits. As a confirmation, phospholamban deficient mice showed no increase in
heart rate after thyroid hormone treatment [20].
On the plasma membranes, T3 exerts direct extragenic actions on the functions other ion
channels such as Na/K ATPase, Na/Ca++exchanger, and some voltage gated K channels (Kv
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1.5, Kv 4.2, Kv 4.3) affecting myocardial and vascular functions [21,22] coordinating electro‐
chemical and mechanical responses of myocardium [23,24]. It prolongs the activation of Na
channels in myocardial cells [25] and induces intracellular Na uptake and secondary activation
of the Na-Ca antiporter, which can partly explain the positive inotropic effect. T3 exerts direct
effect on L-type calcium channels resulting in abbreviation of action potential duration and
possibly L-type calcium channel mRNA expression [26,27].
The strong inotropic activity of thyroid hormones is probably due to an increased number of
β-adrenergic receptors [28]. Circulating cathecholamine levels are in fact the same, but G
protein and β-receptors increase [29]. The sensitivity of cardiovascular system to adrenergic
stimulation does not change by thyroid hormones [30,31]. The changes in the heart rate result
from both an increase in sympathetic tone and decrease in parasympathetic tone [32,33].
These genomic effects fail to explain the fast actions of thyroid hormones on the cardiovascular
system. Non-genomic effects promote rapid changes, such as increased cardiac output [34-36].
The hemodynamic consequences of hyperthyroidism and nongenomic changes on plasma
membranes occur acutely and contribute to these rapid changes. Studies indicate that thyroid
hormone activates acute phosphorylation of phospholamban, and that also partly explains the
homology between thyroid hormone and adrenergic system on the heart [32].
In an experimental study on rats, thyroid hormones upregulate connexin-40, a gap junction
protein of myocardium important for the transport of electrical activity, and this may be one
of the pathogenetic mechanisms of atrial fibrillation in hyperthyroidism [37]. In another animal
study the authors suggested that the connexin-43 phosphorylation was downregulated by T3
in diabetic rats and decrease adaptation of heart to hyperglycemia and this may render the
heart prone to ventricular arrythmias [38]. In fact thyroid hormone receptor alpha 1 is
predominantly expressed in cardiac myocardium and may have an important role in cardiac
myoblast differentiation by ERK kinase dependent process, but its clinical relevance is not
known [39]. Also ERK (extracellular signal-regulated kinase) pathway may have a role in
negative cardiac remodelling and decreased cardiac contractile function in hyperthyroidism,
by inhibition of the Raf-1/ERK pathway by T3 [40,41].
Meanwhile, the thyroid hormone may have direct (without autonomous nervous system)
effects on the sinoatrial node [42,43] and oxidative stress in animal studies [44]. The heart rate
increases due to increased sinoatrial activity, a lower threshold for atrial activity, and a
shortened atrial repolarisation [45,46]. Together with hemodynamic changes, i.e. the volume
preload increases due to activation of the renin-angiotensin system [47], contractility increases
due to increased metabolic demand and the direct effect of the thyroid hormone on heart
muscle [48] and systemic vascular resistance decreases because of triiodotyronine-induced
peripheral vasodilatation [49]. The result is a dramatic increase in cardiac output [50].
Local type 2 iodothyronine deiodinase up-regulation may also be involved in cardiac remod‐
elling via activation of thyroid hormone signalling pathways involving Akt and p38 MAPK
(mitogen-activated protein kinase) in thyrotoxic-dilated cardiomyopathy [51]. Animal studies
show the effects of thyroid hormones on soluble fractions of 5’-nucleosidase activity, via
protein kinase C-related pathway [52]. Preclinical studies blocking Akt by angiotensin-II type
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2 receptor blocker showed that this blockage might prevent thyroxine-mediated cardiac
hypertrophy [53]. Meanwhile, hypertrophied myocytes may be susceptible to apoptotic
stimulation by angiotensin II in hyperthyroidism [54].
Studies on rats show that mitochondrial ultrastructure was damaged in T3 treated hyperthy‐
roid rat heart, leading to energy depletion and cardiac dysfunction [55]. Another study on
hamsters revealed that long term hyperthyroidism cause increased left ventricular interstitial
fibrosis, significant cardiac hypertrophy and deleterious cardiac remodeling characterized by
myocyte lengthening, chamber dilatation, decreased relative wall thickness, increased wall
stress, and impaired global cardiac function whereas cardiomyocyte functions may be
enhanced [56]. Some animal studies Show beneficial effects of angiotensin receptor blockers
on myocytes as improved left ventricular longitudinal strain, heart rate and reduced cardio‐
myocyte width, affecting structural remodelling beyond the anti-tachycardic effect of beta-
blockers [57].
2.3. Hemodynamic effects of thyroid hormones
Hemodynamic effects of thyroid hormones are generally nongenomic and faster, by direct
effects on the heart and blood vessels. In the peripheral vascular system, the rapid use of
oxygen, increased production of metabolic end products and relaxation of arterial smooth
muscle fibres by thyroid hormone cause peripheral vasodilatation [21]. This fall in peripheral
vascular resistance (PVR) plays the central role in all hemodynamic changes caused by thyroid
hormones [58]. Decreased PVR causes an increase in heart rate and selective increase in blood
flow of some organs (skin, skeletal muscles, heart), and a fall in diastolic pressure with
consequent widening of pulse pressure. Vasodilatation without an increase in renal blood flow
causes reduction in renal perfusion and activation of the renin-angiotensin system which
causes sodium retention and increased blood volume [59]. In addition, thyroid hormones
regulate erythropoietin secretion and increased red cell mass may also contribute to blood
volume increase [60]. Improved diastolic relaxation and increased blood volume increased left
ventricular end-diastolic volume (LVEDV). Reduced PVR and increased LVEDV means
increased preload and decreased afterload, thus the stroke volume increases. Increased stroke
volume and increased heart rate leads to a doubling or tripling of cardiac output which cannot
be solely explained by the increased metabolic rate of the body [61].
The importance of the contribution of decreased systemic vascular resistance to the increase
in systemic blood flow in patients with hyperthyroidism is evidenced by studies in which the
administration of arterial vasoconstrictors, atropine and phenylephrine, decreased peripheral
blood flow and cardiac output by 34% in patients with hyperthyroidism but not in normal
subjects [62,63].
2.4. Clinical aspects of hyperthyroidism and subclinical hyperthyroidism on heart
Increased rate and strength of the heart contractility, together with an exaggerated response
of heart rate to exercise is present in hyperthyroid patients who describe this as palpitations.
Diurnal heart rate variations are generally preserved. The most common ECG abnormality is
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sinusal tachycardia and shortened PR interval, and frequently intra-atrial conduction is
prolonged, which is seen as increase in P wave duration. Intraventricular conduction delay in
the form of right bundle branch block is present in around 15% of patients, and atrioventricular
block may also occur due to unknown reasons. The most common rhythm disturbance in
hyperthyroid patients is sinus tachycardia [32]. Its clinical impact however is overshadowed
by that of patients with atrial fibrillation. The prevalence of atrial fibrillation (AF) and less
common forms of supraventricular tachycardia in this disease ranges between 2 to 20 percent
[64,65]. AF is generally accompanied by rapid ventricular response. It is more common in men
and its significance increases by age, after 40 years [65]. As in the case of angina or heart failure,
the development of AF should not be attributed only to hyperthyroidism, and the underlying
organic heart diseases should be investigated.
Atrial fibrillation usually reverses to a sinus rhythm by achievement of a euthyroid state, if the
patient is younger and the duration of hyperthyroidism is not long. The beta-adrenergic
blockade may be effective in controlling the ventricular rate. Increased plasma clearance of
beta-blockers may necessitate higher doses [66]. Among them propranolol has the advantage
of blocking the conversion of T4 to T3 in peripheral tissues, however other cardioselective beta-
blockers have a longer half-life and can be equally effective on the heart. In cardiac arrhythmias
intravascular infusion of calcium blockers should be avoided due to the risk of a further fall
in PVR [67]. It is still controversial whether the patients with AF should have anticoagulant
therapy to prevent systemic embolization. It is advised to evaluate each patient on a case-by-
case basis, and determine the risk of bleeding over embolization [68,69]. In younger patients
with hyperthyroidism and AF, who do not have other heart disease, hypertension, or inde‐
pendent risk factors for embolization, the risk of anticoagulant therapy may suppress its
benefits. But it would be appropriate to administer anticoagulant agents to older patients with
known or suspected heart diseases, or AF with longer duration. When oral anticoagulants will
be used, it should be considered that hyperthyroid patients will need smaller doses than
euthyroid ones, due to faster elimination of vitamin-K dependent clotting factors [70].
In the patients with AF the maintenance of sinus rhythm is not possible until the euthyroid
state is restored, so electrical cardioversion is not recommended without confirming the
euthyroid status.
Many hyperthyroid patients experience exercise intolerance and exertional dyspnea, in part
because of weakness in the skeletal and respiratory muscle [71] and also due to inability to
increase heart rate or lower vascular resistance further, as normally occurs in exercise [72]. The
tem “high output heart failure” has not been used in recent decades, because it is clear that the
heart is still able to increase cardiac output at rest and with exercise. In the setting of low
vascular resistance and decreased preload, the cardiac functional reserve is compromised and
cannot rise further to accommodate the demands of submaximal or maximal exercise [73].
About 6% of thyrotoxic patients develop heart failure and less than 1% develop dilated
cardiomyopathy with impaired left ventricular systolic dysfunction, due to the tachycardia-
mediated mechanism leading to an increased level of cytosolic calcium during diastole, with
reduced contractility of the ventricle and diastolic dysfunction, often with tricuspid regurgi‐
tation [74]. In the recent study of Yue et al, diastolic dysfunction was more prominent in
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thyrotoxic patients older than 40 years of age, whereas in younger ones marked reduction in
peripheral vascular resistance and increased cardiac output were prominent [75].
Hyperthyroidism may complicate or cause pre-existing cardiac disease because of increased
myocardial oxygen demand, increased contractility and heart rate, and may cause silent
coronary artery disease, anginas or compensated heart failure and even endothelial dysfunc‐
tion [76]. Treatment of heart failure with tachycardia should include a beta-blocker, by
considering its contraindications in each patient. Furosemide may help to reverse the volume
overload, but digoxin is less beneficial when compared with euthyroid heart failure patients
because there may be relative resistance to its action, due to greater blood volume (distribution)
and the need to block more Na-K-ATPase in myocardium [70].
Subclinical hyperthyroidism is a state characterised by low serum thyrotropin levels and
normal serum thyroid hormone concentrations. Over recent decades this state has also been
found to be associated with some abnormalities in cardiac function. Enhanced systolic function
and impaired diastolic function due to slowed myocardial relaxation may cause increased left
ventricular mass in these subjects, together with increased heart rate and arrhythmias by
similar mechanisms as overt hyperthyroidism [77,78]. In people over 60 years of age subclinical
hyperthyroidism was associated with a tripled risk of atrial fibrillation during a 10-year follow-
up period [79]. In a recent cross-sectional study with 29 patients, subclinical hyperthyroidism
was found to be related with impaired functional response to exercise with low oxygen
consumption and exercise threshold, together with slower heart rate recovery [80].
Besides  antithyroid  treatment  strategies,  beta-blocker  therapy  reduces  heart  rate  and
improves  left  ventricular  mass,  but  positive  inotropic  response  persists.  This  subclinical
hyperthyroidism is associated with increased cardiovascular mortality [81]. In the study of
Heeringa et al with 1,426 patients, it was shown that even the high-normal thyroid function
may  increase  the  risk  of  AF  [82].  Besides  increased  AF  and  thromboembolic  events,
increased left ventricular mass and left ventricular function may be the reason. Thus, it is
advised to measure serum thyrotropin in all elderly patients with systolic hypertension, a
widened  blood  pressure,  recent-onset  angina,  atrial  fibrillation  and  any  exacerbation  of
ischemic heart disease and treat it [72,83].
3. Progressive infiltrative ophtalmopathy in hyperthyroidism
3.1. Hyperthyroidism and eye disease
Thyroid eye disease (TED), also called thyroid-associated ophthalmopathy (TAO) and Graves'
ophthalmopathy (GO), affects 25–50% of patients with Graves' disease [84]. Regardless of
whether hyperthyroidism occurs first, the signs and symptoms of GO become manifest in 85%
of patients within 18 months [85]. The clinical features are usually mild. Most common
symptoms are; ocular irritation with redness and tearing,, sensitivity to light, double vision,
blurring of vision, and feeling a pressure sensation behind the eyes. On physical examination,
extraocular muscle dysfunction, proptosis, periorbital and eyelid edema, conjunctival chemos,
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lid lag and retraction (or stare), or exposure keratitis may be detected [86]. Most patients
experience only the minor congestive signs of TAO (chemosis, injection, lid edema), with
improvement in several months without treatment. Approximately 28% of TAO cases are
severe and symptomatic for several years. Symptoms and signs include, restricted motility
leading to diplopia, exposure keratopathy, optic neuropathy and loss of vision [87,88].
TAO can be divided into two clinical stages; congestive and fibrotic. In the congestive or
inflammatory stage, auto-immunity leads to inflammatory cellular infiltration of the muscles
and transformation of fibroblasts into adipose tissue. The fibrotic stage is characterized by
fibrosis which causes proptosis and strabismus [89,90].
3.2. Pathophysiology
In TAO, the most important pathological changes are enlarged extraocular muscles and
increased orbital fat. These changes result from a complex interplay among orbital fibroblasts,
immune cells, cytokines, auto-antibodies, genetics, and environmental factors [84].
Interactions between orbital fibroblasts, immune cells, cytokines and autoantibodies
Patients with TAO, orbital tissue is infiltrated by inflammatory cells (T helper type 1 (Th1)
and T helper type 2 (Th2) lymphocytes, B lymphocytes, mast cells, and macrophages) [91,92].
These  cells  release  cytokines  which  participate  in  tissue  reactivity  and  remodeling.
Normally, the antigens to which lymphocytes respond are foreign, and several tolerance
mechanisms act to prevent the development of reactivity to self-antigens or autoimmuni‐
ty,  but  these  tolerance  mechanisms  sometimes  fail  and  autoimmunity  develops  [93,94].
Fibroblasts are a highly interactive cell type, described as “sentinel cells” [95]. They, respond
to immune stimulation and actively participate  in the inflammatory pathway [96,97].  In
patients  with  TAO,  orbital  fibroblasts  synthesize  excess  glycosaminoglycans  (GAGs),
including  hyaluronan.  These  can  differentiate  into  adipocytes,  leading  to  the  accumula‐
tion of fat [98]. Orbital fibroblasts do not express the IL-1 receptor antagonist at levels found
in other fibroblasts,  but also display lymphocyte costimulatory molecules such as CD40.
These differentations result  in excessively high levels  of  Cox-2 and PGE2  in response to
proinflammatory  cytokines  [99,100].  T  lymphocytes  in  the  orbital  tissue  interact  with
fibroblasts. This interaction results with activation and proliferation of fibroblasts, synthe‐
sis of extracellular macromolecules, and differentiation to adipocytes [101]. A summary of
this model for the pathogenesis of TED is depicted in Figure 1 [102].
Autoantigen expression by orbital fibroblasts results in T lymphocyte accumulation to the orbit
[103]. The autoantigen may be a TSH receptor (TSH-R) or an insulin-like growth factor-1
receptor (IGF-1R) [103,104]. T lymphocytes in the orbital tissue induce fibroblast proliferation
and hyaluronan synthesis. This result in orbital tissue remodeling [101]. Stimulation of orbital
fibroblasts by T lymphocytes results in production of chemokines (e.g. IL-16, RANTES) and
cytokines (e.g. IL-6). These molecules initiate migration of T and B lymphocytes to the orbital
tissue and increase fibroblast presentation of autoantigens [97,101,105). Costimulatory
molecules, adhesion molecules, and cytokines like IFNγ, IL-1β, and TNFα play an important
role in the interaction between T lymphocytes and fibroblasts. One of the communication
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pathways of T lymphocytes and orbital fibroblasts is the CD40-CD40 ligand pathway
[97,100,101]. In TAO orbital fibroblasts express high levels of CD40 [97,106]. Activation by
CD40L induces hyaluronan synthesis, IL-6 and IL-8, Cox-2 and PGE2 [97,101,107].
T lymphocyte-mediated activated fibroblasts release factors which promote and activate the
proliferation of T lymphocytes. In this way fibroblasts perpetuate inflammation [101,108].
Antonelli et al. found that orbital fibroblasts from TAO patients may modulate the activity of
T lymphocytes through the production of CXCL10. Serum CXCL10 levels were higher in active
TAO patients than in those with inactive disease. CXCL10 release enhances the migration of
T lymphocytes into the orbital tissue. These lymphocytes secrete IFNγ and TNFα. There is a
positive feedback between CXCL10 and IFNγ – TNFα. Peroxisome proliferator-activated
receptor-gamma (PPAR-γ) activation has an inhibitory role in this process [108]. Feldon et al.
found that activated human T lymphocytes drive the differentiation of human fibroblasts to
adipocytes. They showed that human T cells, when activated, strongly express Cox-2 and
produce PGs, possibly 15d-PGJ2, that are PPAR-γ ligands and human T cells also produce
PGD2. These findings showed that PGD2 converts to the PGJ series of PGs with the final product
being 15d-PGJ2, a notable potent PPAR-γ ligand [109-111]. Feldon et al. also showed that
human orbital fibroblasts express PPAR-γ and that 15d-PGJ2, PGD2, and 15d-PGD2 strongly
induce adipogenesis [109]. Natural and synthetic activators of PPAR-γ stimulate lipid
accumulation and the expression and secretion of adiponectin [112,113]. PPAR-γ levels are
higher in orbital tissue from patients with active TAO [108,114].
Chen et al. showed higher mRNA levels of a macrophage chemoattractant called C-C motif
chemokine ligand-2 (CCL2)/monocyte chemoattractant protein-1 (MCP-1) and dense infiltra‐
tion with macrophages in the orbital fat compared with normal controls [115].
3.3. Smoking
There is a strong and consistent association between smoking and TAO [116]. But the exact
mechanism by which smoking affects TAO is not known. Formation of superoxide radicals
and tissue hypoxia could be responsible. Cigarette smoke either contains or can generate a
variety of oxidants and free radicals [117]. Orbital fibroblasts can be induced by tissue hypoxia
(5% CO2 and 95% N2) and superoxide radicals, thus they proliferate and synthesize GAGs
[118,119]. Mack et al. cultured orbital fibroblasts, obtained from patients undergoing orbital
decompression for severe GO. They showed that, inreased human leukocyte antigen (HLA-
DR) expression of orbital fibroblasts occurred in response to nicotine and tar only in the
presence of interferon-γ. These findings suggest that there is an interaction between smoking
and orbital immune responses [120]. Many studies demonstrated a dose-response relationship
between the numbers of cigarettes smoked per day and TAO [121]. Smokers suffer more severe
TAO than non-smokers. Smoking increases the progression of TAO after radioiodine therapy
for hyperthyroidism [116]. Eckstein et al. demonstrated that smoking influences the course of
TAO during treatment in a dose dependent manner. The response to treatment is delayed and
considerably poorer in smokers [122]. Pfeilschifter et al. showed that former smokers had a
significantly lower risk for the occurrence of proptosis and diplopia than active smokers with
a comparable lifetime cigarette consump
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Figure 1. Pathophysiology of thyroid eye disease
3.4. Genetics
For the development of TAO the presence of autoimmune thyroid disease appears to be
necessary, but not sufficient [124]. The interaction between genetic and environmental factors
plays a major role for the development of TAO in a patient with autoimmune thyroid disease.
TAO and autoimmune thyroid disease share a common etiology; regardless of which occurs
first, the other develops within 18 months in 80% of affected patients [125]. Polymorphic
variations in individual somatic genes or groups of genes known to be involved in thyroid
autoimmunity might also predispose to TAO.
Thymic stromal lymphopoietin (tslp) gene promoter polymorphisms
The role of TSLP in Th17 cell differentiation implicates TSLP in the pathogenesis of TAO. Tsai
et al. genotyped 470 patients with TAO at 3 single nucleotide polymorphisms (SNPs) in TSLP
and determined the serum concentrations of TSLP in 432 patients and 272 controls. They
showed that TSLP polymorphisms are associated with TAO and that expression levels of TSLP
are higher in patients than in control subjects. In addition, they concluded that TSLP mediates
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the differentiation of CD4+T cells into Th17 cells. According to this study the TSLP gene may
be a relevant candidate gene for susceptibility to TAO. TSLP genotypes may be used as genetic
markers for the diagnosis and prognosis of TAO [126].
Toll-like receptor gene polymorphisms
Toll-like receptors (TLRs) are a family of pattern-recognition receptors, which play a role in
eliciting innate/adaptive immune responses and developing chronic inflammation. Liao et al
evaluated 6 TLR-4 and 2 TLR-9 gene polymorphisms in 471 GD patients (200 patients with
TAO and 271 patients without TAO) from a Taiwan Chinese population. There was no
statistically significant difference in the genotypic and allelic frequencies of TLR-4 and TLR-9
gene polymorphisms between the GD patients with and without TAO. In the sex-stratified
analyses they showed that the association between TLR-9 gene polymorphism and the TAO
phenotype was more pronounced in the male patients. Their data suggest that TLR-9 gene
polymorphisms are significantly associated with increased susceptibility of ophthalmopathy
in male GD patients [127].
Polymorphisms of B7 molecules (CD80 and CD86)
Liao et al. evaluated genotypes of CD80 and CD86 polymorphism in GD patients. They found
that the frequency of C allele at position rs_9831894 of the CD86 gene is different in patients
with GD (with and without TAO). They showed that the G-A haplotype has a protective effect
in the development of TAO among patients with GD. Their data suggest that the polymor‐
phisms of the CD86 gene may be used as genetic markers for making the diagnosis and
prognosis of TAO [128].
Interleukin-1beta (IL1β) polymorphisms
Recent studies have demonstrated that IL1β plays a role in the development of TAO by
inducing adipogenesis and accumulation of GAGs and prostaglandin E2 (PGE2) [129,130]. Liu
et al. found that the SNPs rs3917368 and rs1143643 in the 3′ UTR and intron regions of IL1β
and patients with the genotypes containing both rs3917368 A/A and rs1143643 A/A may bear
a higher risk of developing TAO. Thus we can speculate that IL1β polymorphisms can be
related with the development of TAO in GD [131].
Cytotoxic T lymphocyte antigen-4
Vaidya et al. firstly reported an association between CTLA-4A/G polymorphism at codon 17
and TAO [132], but this data was not confirmed by Allahabadia et al. in a larger cohort of
patients [133]. Daroszewski et al. evaluated the relation between soluable CTLA-4 level and
clinical manifestation of TAO and CTLA-4 gene polymorphisms. They found higher levels
of Serum sCTLA-4 in the TAO group than in controls. The level of sCTLA-4 was higher in
severe TAO patients than in non-severe cases. They showed for the first time that the pres‐
ence of the CTLA-4 gene polymorphisms Jo31 and CT60 were related with elevated sCTLA-4
levels [134]. These data suggest that the polymorphisms of the CTLA-4 gene may be used as
a genetic marker for making the diagnosis and prognosis of TAO. The role of sCTLA-4 and
its full-length cell-bound analogue in autoimmunity remains uncertain.
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PPAR-γ gene polymorphism
The PPAR-γ transcription factor is involved in both adipogenesis and inflammation which
have been implicated in the pathogenesis of TAO. Alevizaki et al. found no difference in the
distribution of the Pro(12)Ala PPAR-γ gene polymorphism between GD patients with and
without TAO. But they showed that PPAR-γ polymorphism carriers had lower TSH-Rab levels
and lower clinical activity scores (CAS). According to this study patients with TAO who have
this polymorphism are associated with less-severe and less-active disease [135].
IL-23R polymorphisms
Huber et al. demonstrated that two IL-23R polymorphisms (rs10889677 and rs2201841) were
associated with TAO. According to this study we can speculate that these variants may induce
TAO by changing the expression and/or function of IL-23R, by promoting a pro-inflammatory
signaling cascade [136].
Protein tyrosine phosphatase-22
Lymphoid protein tyrosine phosphatase (LYP, aka PTPN-22) represents another negative
regulator of T cell activation. Syed et al. found an association between certain single nucleotide
polymorphisms (SNPs) in the protein tyrosine phosphatase (PTP) called PTPN12 and in‐
creased risk of mild/moderate ophthalmopathy [137]. But this data should be confirmed in
larger studies.
Nuclear factor (NF)-[kappa]B1
Kurylowicz et al. showed a correlation between a polymorphism in the NF-[kappa]B1 gene
promoter (-94ins/del adenine, thymine, thymine, guanine) and the development of TAO [138].
Human leukocyte antigen (HLA)
HLA class I-II genes are related for the development of TAO [139]. Akaishi et al. found TAO
patients with major extraocular muscle involvement have had a higher frequency of the HLA-
DRB1*16 allele, but patients with minor extraocular muscle involvement have had a higher
frequency of the HLA-DRB1*03 allele [140]. In another study an association between HLA-
A11,-B5,-DW12 and-DR14 and TAO has been found [141,142].
3.5. Cytokines
Autoimmune thyroid disease involves the activation of multiple cytokine networks. Serum
IL-6 levels were greater in the patients with TAO than in those without eye disease [143] and
both Th1-and Th2-derived cytokines were elevated in TAO patients compared with control
samples [144]. Chen et al. found that the exaggerated capacity of orbital fibroblasts to express
high levels of both IL-6 and its receptor in an anatomic site-selective manner could represent
an important basis for immune responses in TAO [145]. Higher serum levels of IL-17 were
obtained in TAO patients than in controls. Serum IL-17 concentration had significant correla‐
tion with CAS [146]. Significantly higher PAI-1 [147] and IgE levels [148] were found in TAO
patients than in the control groups.
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3.6. Imaging procedures in TAO
Ultrasound (US)
US is of primary importance in orbital pathology because of its safety, non-invasiveness, short
time of investigation, low cost, lack of radiation and application without need to prepare the
patient. In endocrine orbitopathy; the A scan demonstrates echographical widening of the
peripheral orbital space and a widening of the muscle echo, while the B scan shows a high
internal echo of the connective tissue septa, increased reflection of the muscle belly and
distension of the retrobulbar optic nerve sheaths, enlargement of lacrimal gland and dilatation
of the superior ophthalmic vein [149]. Although it has many advantages, US cannot effectively
display the muscles at the apex of the orbit. US is not as effective as other diagnostic procedures
in delineating the relationship of orbital pathology to contiguous structures, nor is it reliable
in imaging lesions of either the posterior orbit or those involving the bone walls [150].
Computed tomography (CT)
According to differential X-ray absorption CT can differentiate normal and abnormal struc‐
tures of different tissue density. In CT orbital fat images as a black, low-density area, while in
contrast to this extraocular muscles and the optic nerve image as higher-density areas [151].
The primary areas of orbital involvement are extraocular muscles, and CT findings correlate
with clinical impressions of the severity of extraocular muscle enlargement [152]. Muscle
involvement on CT of TAO is usually limited to the non-tendonous portion of the muscle. Due
to compression of the optic nerve by enlarged extraocular muscles near the orbital apex, optic
nerve dysfunction can be seen in TAO [153]. Other findings that may be noted on CT are
lachrymal gland enlargement, a dilated superior opthalmic vein, muscle belly enlargement
and increase in orbital fat volume [154,55]. CT imaging is a non-invasive, simple, fast, and cost
effective imaging procedure. Furthermore, having high sensitivity and correlation with clinical
findings, CT imaging should be considered first during diagnostic evaluation of TAO.
Magnetic resonance imaging (MRI)
Pulse sequences that examine T2 in MRI can estimate the water content of tissues. In TAO
lymphocytes infiltrate the orbital tissue that causes fibroblast stimulation. Fibroblasts produce
large amounts of GAGs. By binding large amounts of water, GAGs cause edema. Increased
water content of thickened extra-ocular muscles cause elevated T2 [156]. In TAO there are two
different phases with disease activity. Medical treatment can be effective in the active stage.
Therefore, for predicting the outcome of medical management the evaluation of disease
activity is important. Yokoyama et al. investigated whether MRI could assess the disease
activity in TAO. They found that MRI is not only a useful tool for detection of extraocular
muscle enlargement, but also for assessment of disease activity in TAO [157]. In conclusion,
MRI is useful to assess TAO. But cost and availability are current limitations of this modality.
Therefore, MRI should be used for the management of TAO in specialized patients and clinics.
Octreoscan (OCT)
It is thought that radionuclide accumulation is probably due to binding to somatostatin
receptors on lymphocytes, myoblasts, fibroblasts and endothelial cells. Another explanation
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is local blood pooling due to venous stasis by the orbital inflammation [158,159]. Krassas et al.
found that OCT positivity is higher in Graves' patients with than in those without ophthalm‐
opathy, and higher in patients with active TAO than in those with inactive TAO [160]. Postema
et al. demonstrated that OCT positivity correlates with activity of the TAO such as high CAS
[161]. Thus, a positive orbital OCT means clinically active TAO, in which immunosuppressive
treatment might be of therapeutic benefit [162]. However, limitations such as cost, non-
negligible radiation burden, non-specific examination for TAO, and finally, lack of evaluation
of eye muscle swelling restrict the widespread use of this technique [163]. Orbital OCT is
mainly indicated to select patients with TAO who will benefit from immunosuppression [162].
3.7. Other diagnostic techniques
Kuo et al. were first described in a positron emission tomography (PET/CT) study in a patient
with TAO. The detection of inflammation by 18F-fluorodeoxyglucose (FDG) uptake was
sensitive and objectively demonstrable by this semi-quantitative imaging method [164].
García-Rojas et al. carried out the first prospective study. FDG uptake of extra-ocular muscles
was statistically different between patients with and without TAO. In cases with TAO where
clinical doubt exists, PET/CT provides valuable and useful information for the diagnosis,
characterization, and therapeutic decision [165]. Further research is required to define the role
of FDG-PET/CT in the management of TAO.
Another tool to measure orbital inflammation is the uptake of radioactively labeled substances,
such as 67Gallium (Ga) citrate [166] and 99mTechnetium (Tc)-labeled agents [167,168]. In medical
literature there are few studies about these nuclear imaging techniques.
3.8. Clinical classification systems
The treatment for TAO varies according to the level of disease activity. Thus, methods have
been proposed to determine whether TAO is active (33). There are two main scoring systems
[169,170]:
1. NOSPECS (No signs or symptoms; Only signs; Soft tissue involvement with symptoms
and signs; Proptosis; Eye muscle involvement; Corneal involvement; Sight loss)
2. CAS (Clinical Activity Score) systems.
Neither NOSPECS nor CAS are both specific and completely reliable, but CAS is a simple
office-based tool. The modified NOSPECS criteria include lid retraction, soft tissue inflamma‐
tion, proptosis, size difference, extra-ocular muscle involvement, corneal defects, and optic
nerve compression [169]. CAS demonstrates the presence or absence of seven symptoms or
signs that indicate inflammation (Table-1) [171].
The score ranges from 0 to 7, with 0 to 2 characteristics indicating inactive TAO and 3 to 7
characteristics indicating active TAO. The CAS has a high predictive value for the outcome of
immunosuppressive treatment in TAO. The main determinant of therapeutic outcome is
disease activity, not disease duration [172]. In addition, the severity of disease should be
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assessed (Table-2). Dysthyroid optic neuropathy, corneal breakdown or both indicate that the
TAO is sight-threatening and requires immediate treatment [116].
∙ Spontaneous retrobulbar pain
∙ Pain with eye movement
∙ Redness of the eyelids
∙ Redness of the conjunctiva
∙ Swelling of the eyelids
∙ Swelling of the caruncle
∙ Conjunctival edema (chemosis)
Table 1. Components of the Clinical Activity Score
∙ Lid aperture
∙ Swelling of the eyelids
∙ Redness of the eyelids
∙ Redness of the conjunctivae
∙ Conjunctival edema
∙ Inflammation of the caruncle or plica
∙ Exophthalmos
∙ Subjective diplopia score
∙ Eye muscle involvement
∙ Corneal involvement
∙ Optic nerve involvement
Table 2. Assesment of Disease Severity
3.9. Management
Smoking and TAO
Patients should be encouraged to quit smoking. In an observational study smoking cessation
has been associated with a decreased risk of the development of exophthalmos and diplopia
in patients with Graves' disease [171].
Management of hyperthyroidism in patients with TAO
Uncontrolled thyroid functions (both hyper-and hypothyroidism) are related to severe TAO.
Patients with hyperthyroidism can be treated with anti-thyroid drugs (ATDs), radioactive
iodine (RAI) therapy and surgical therapy. Some different studies have shown improve‐
ment  in  TAO  [173]  by  indirect  beneficial  effects  [174]  and  a  gradual  decrease  in  TSH-
receptor antibody (TRAb) levels during ATDs treatment [175]. There are confliciting reports
in  medical  literature  about  RAI  therapy and severe  TAO [176,177].  But  this  association
cannot be excluded. This risk can be eliminated by therapy with oral glucocorticoids (GCs)
after RAI therapy and avoiding post-treatment hypothyroidism [116]. Thyroidectomy is an
effective treatment choice for the definitive cure of hyperthyroidism. Wilhelm et al. showed
that  near-total/total  thyroidectomy  is  safe  and  superior  to  subtotal  thyroidectomy  for
management of hyperthyroidism in Graves' disease [178]. According to the European Group
on Graves' Orbitopathy (EUGOGO) Consensus Statement; ATD therapy and thyroidecto‐
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my  do  not  affect  the  course  of  TAO.  No  particular  ATD  or  regimen,  nor  any  type  of
thyroidectomy (subtotal or total) has been demonstrated to have any advantages in terms
of outcome of TAO in hyperthyroidism [116].
3.10. Pharmacologic treatments
TAO represents a complex therapeutic problem. Currently available pharmacologic treatment
options result in a partial or absent response of the ophthalmopathy. Up to date available
treatments for TAO are as follows:
Glucocorticoids
Glucocorticoids (GCs) are effective treatment options in TAO because of their antiinflamma‐
tory and immunosuppressive actions (96). Moreover they decrease GAGs synthesis and
secretion by orbital fibroblasts [180].
GCs can be administrated by oral, local (retrobulbar or subconjunctival) and intravenous
routes. Oral GCs are generally used in high doses (prednisone, 60–100 mg/day or equiva‐
lent  doses  of  other  steroids)  and  for  long-time  periods  (several  months).  It  has  been
demonstrated  that  high-dose  oral  GCs  are  effective  on  soft  tissue  changes  and  optic
neuropathy. But when its dose is tapered down and/or withdrawn, recurrence of active eye
disease is a frequent problem [181]. In slightly more than 60% of cases (range: 40–100%)
favorable effects of high-dose oral GCs are reported. GCs have also been used intravenous‐
ly.  In  most  studies  effects  have  been  observed  on  inflammatory  signs  and  optic  nerve
involvement.  But  the effects  on extra-ocular  muscle involvement,  and especially propto‐
sis, have not been constantly impressive [90].
In most studies patients treated with intravenous GCs have had more favorable results
compared with patients treated with oral GCs [18,183]. But in almost all studies treatment with
intravenous GCs have been associated with, in the interpulse periods, or followed by (often
prolonged) treatment with oral GCs. Moreover there have been biases in patient selections
(different degrees of disease activity and duration). Bartalena et al. compared the efficacy and
safety of three doses of intravenous (IV) methylprednisolone (2.25, 4.98, or 7.47 g in 12 weekly
infusions) in patients with moderate to severe and active TAO. They demonstrated that the
use of a cumulative dose of 7.47 g of methylprednisolone provides short-term advantage over
lower doses. This benefit was transient and associated with slightly greater toxicity. According
to this study we can speculate that an intermediate-dose regimen be used in most cases and
the high-dose regimen be reserved to the most severe cases of TAO [184]. Systemic glucocor‐
ticoid therapy relates with some side effects and complications. Therefore, local (retrobulbar
or subconjunctival) glucocorticoid therapy has been raised. But in most studies local gluco‐
corticoid therapy had been less effective than systemic administration. As a result, local
glucocorticoid therapy can be a treatment option in patients with active ophthalmopathy and
with major contraindications to the systemic administration [181].
GCs are generally used for severe and active TAO [90]. Furthermore, patients with sight-
threatening dysthyroid optic neuropathy should be treated with high-dose intravenous or oral
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glucocorticoid agents [116]. Additionally, there are some case reports in medical literature,
who had severe complicatons related with high-dose glucocorticoid pulse therapy [185].
Somatostatin (SST) analogues
SST receptors (SSTR) are expressed in many tissues, including activated lymphocytes. OCT
was proposed as a method to evaluate orbital inflammation in TAO. The use of the SST analog,
octreotide, was first reported in TAO patients by Chang et al [186]. Uysal et al. evaluated the
effect of octreotide treatment in nine patients with TAO. Seven of the patients showed
improvement in CAS. Proptosis improved either slightly or significantly in seven patients.
None of the patients has showed deterioration in the eye according to their findings [187]. A
major disadvantage of octreotide is its short half-life, which requires multiple injections. To
overcome this limitation, new long-acting SST analogs (lanreotide / octreotide-LAR) have been
developed. Stan et al. carried out a randomized, double-blind, placebo-controlled trial of
octreotide-LAR for treatment of TAO. In octreotide-LAR-treated patients, the CAS improved
with a greater degree than in the placebo group. They noted improvement in eyelid fissure
width, which suggest that octreotide LAR treatment may be effective in TAO patients with
significant lid retraction [188]. In another study Krassas et al. aimed to investigate the orbital
Indium-111-pentetreotide activity after treatment with octreotide and lanreotide in patients
with TAO. All patients treated with SST analogs had a negative follow-up OCT, whereas
controls had a positive OCT. Both NOSPECS score and CAS had improved in the treatment
group, but there have been no changes in control subjects [189]. Most common side effects of
SST analog therapy in TAO patients were mild gastrointestinal symptoms occurring during
the first week of treatment. Because of minimal side effects and proven efficacy, SST analogs
could be a treatment option in selected patients. But we need further large, multi-center,
prospective and randomized clinical trials and a comparable series of patients with other
established treatment options, to achieve more accurate outcomes. In addition, the high cost
of this treatment must also be taken into account.
Intravenous immunoglobulins (IVIG)
Antonelli et al. was published as the first non-randomized study on the use of IVIGs for TAO.
They treated 7 patients with high-dose IVIGs alone (400 mg/kg/day for 5 consecutive days; the
cycle was repeated five times at 3-week intervals) and 7 patients with IVIGs associated with
orbital radiotherapy. The results were compared with a historical group of patients previously
treated with high-dose GCs and orbital radiotherapy. They found that IVIGs, either alone or
combined with orbital radiotherapy, had improved the ocular conditions. This result did not
differ from those obtained in the historical group [190]. In a randomized trial by Kahaly et al.
19 patients with active TAO were treated with a 20-week course of oral prednisolone (P,
starting dose 100 mg/day), and 21 received 1g immunoglobulin/kg body weight for 2 consec‐
utive days every 3 weeks. The immunoglobulin course was repeated six times. The degree of
clinical improvement between two groups was not significant. There was a marked reduction
of thyroid antibody titres in the immunoglobulin group. Side effects were more frequent and
severe during P than during immunoglobulin therapy [191]. But another study by Seppel et
al. failed to show any beneficial effects of IVIGs in TAO [192]. In summary, treatment studies
with IVIGs include small numbers of patients and all of them are not randomized. In addition
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to this, treatment is quite expensive and is related with disease transmission using plasma-
derived products. More prospective, randomized and controlled trials, which includes large
series of patients are required to obtain more accurate results.
Immunosuppressive drugs
a. Cyclosporine A (CyA): The first report by Weetman et al. showed that CyA had positive
effects  on  ocular-muscle  function,  visual  acuity,  exophthalmos  and orbital  muscle  swel‐
ling [193]. Prummel et al. compared two groups of 18 patients each of which were treated
with either cyclosporine or prednisone. At the end of the study, treatment response was
observed  in  11  patients  treated  with  prednisone,  but  only  in  4  patients  treated  with
cyclosporine [194]. Weissel et al. treated 8 patients with TAO, all of whom had compres‐
sive optic nerve disease (CON), by a combined treatment with CyA and cortisone. CON
disappeared completely in all patients [195]. In summary, the use of CyA has been reported
in several studies. Given the side effects of CyA, some of which can be severe, it should
not be considered as a first-line treatment in TAO. The use of CyA might be maintained
in patients who are resistant to GCs alone, and in whom the persistent activity of the disease
warrants  a  continuing  medical  intervention.  According  to  the  recent  European  Thyroid
Association survey CyA or azathioprine were indicated as suitable therapeutic options by
only 6% and 2% of respondents respectively [196].
b. Methotrexate (MTX): MTX is not a novel drug, but it has not systematically been evaluated
in TAO management. Smith et al. carried out the unique study on the use of MTX for non-
infectious orbital inflammatory disorders like TAO. They included 14 patients, and three of
them had TAO. All three patients with TAO had an improvement in their ocular conditions
after MTX treatment [196] According to the recent European Thyroid Association survey MTX
was indicated as a therapeutic option by only 1% of respondents [197]. MTX has many dose-
dependent and reversible side effects and should not be used as a first-line treatment. In
patients with GC dependency, it can be used at low doses with the aim of reducing the dose
of GCs. However, to clarify the effectiveness of MTX in TAO management we need more
controlled and randomized prospective studies.
Antioxidants
Bouzas et al. carried out a prospective, nonrandomized, comparative study on the effects of
the antioxidant agents allopurinol and nicotinamide in TAO patients. Ocular conditions
significantly improved in antioxidant-treated patients, more than placebo-treated patients
[198]. Yoon et al. investigated the inhibitory effect of quercetin on inflammation in cultured
whole orbital tissue. Quercetin had a significant suppression of tissue IL-6,IL-8, IL-1β and
TNFα mRNA expression in cultured orbital tissues from three TAO samples relative to
untreated control tissue [199]. Marcocci et al. demonstrated that selenium administration (100
μg twice daily) significantly improved quality of life, reduced ocular involvement, and slowed
progression of the disease in patients with mild TAO [200].
There is limited data about treatment TAO with antioxidants. We need larger, prospective and
randomized trials to clarify the role of antioxidant agents in the treatment of TAO.
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Cytokine antagonists
Chang et al. aimed to determine the effects of pentoxifylline (Ptx); a cytokine antagonist, on
fibroblasts derived from patients with Graves' ophthalmopathy. Ptx treatment caused a dose-
dependent inhibition of serum-driven fibroblast proliferation and glycosaminoglycan synthe‐
sis [201]. Balazs et al. showed that Ptx has had beneficial effects on inflammatory symptoms
of TAO and associated laboratory parameters [202]. In another study Ptx has improved the
quality of life (QOL) of patients in the inactive phase of TAO [203]. According to these studies
Ptx may be an effective and promising drug in the treatment of TAO.
TNF-α antagonists
Paridaens et al. assessed the effect of etanercept on clinical signs in TAO. After treatment the
mean CAS and ophthalmopathy index (OI) had decreased significantly. No adverse effects
were noted [204]. İnfliximab administration resulted with a significant reduction of inflam‐
mation and improvement of visual function without noticeable short-term side effects in two
patients with active TAO [205,206]. But randomized prospective clinical trials are needed to
obtain whether TNF-α antagonists are effective in reducing the inflammatory symptoms of
TAO, and can be administered safely for a long-term period without serious side effects.
Rituximab (RTX)
A patient with TAO, who was unresponsive to steroids, was treated with RTX. The CAS
declined from 5 to 2 in 3 months and the patient had peripheral B-cell depletion [207]. When
the effect of RTX therapy was compared with IV GCs, RTX had positively affected the clinical
course of TAO, independently of either thyroid function or circulating antithyroid antibodies,
including TSH receptor antibody [208]. Silkiss et al. demonstrated a statistically significant
decrease in CAS from the baseline value. B-cell depletion had been observed and was well
tolerated, and there were no adverse effects from the RTX infusions [206]. There is currently
insufficient evidence to support the use of RTX in patients with TAO. We need large rando‐
mised conrolled trials (RCTs) for investigating the efficacy and safety of RTX versus placebo
or corticosteroids in patients with active TAO to make adequate judgement of this novel
therapy for this condition
Rapamycin
A case of TAO, with dysthyroid optic neuropathy, who was refractory to steroids and orbital
decompression surgery reported. Symptoms, visual acuity, color plate testing, and visual fields
of the patient had been improved; despite the prednisone tapering [210]. On the basis the
pathogenesis of TAO, rapamycin can be considered as a therapeutic option. But we need more
RCTs to assess the efficacy and safety of this drug.
Colchicine
A randomized clinical study showed that colchicine had a beneficial effect on the inflammatory
phase of TAO. Therefore, it was equally effective when compared to the classic treatment with
corticosteroids, but safer and better tolerated [211]. Due to the lack of controlled trials, it is not
clear that these effects were related to the natural history of the ophthalmopathy or to the
effects of the drug.
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Thalidomide
Thalidomide plays a role in inhibiting adipogenesis of orbital fibroblasts in TAO [212]. Han et
al. demonstrated the immunoregulatory effect of thalidomide on peripheral blood mononu‐
clear cells in patients with TAO [213].
Peroxisome proliferator-activated receptor (PPAR) agonists / antagonists
Orbital fibroblasts from patients with TAO have treated with rosiglitazone, and the results
suggested that TSHR expression in TAO orbital preadipocyte fibroblasts is linked to adipo‐
genesis [214]. Several case reports of TAO exacerbation following the initiation of PPAR
agonists have been reported in the literature [215,216]. These findings suggest that novel drugs
which antagonize the PPAR signalling system can also be considered as a treatment option in
TAO. The effects of PPAR-γ activation on CXCL10, CXCL9 and CXCL11 secretion in orbital
fibroblasts and preadipocytes were evaluated. The inhibitory role of PPAR-γ activation in the
process demonstrated [217,218].These studies suggest that PPAR agonists can also be consid‐
ered as a treatment option in TAO. There are conflicting reports in the medical literature,
regarding the use of PPAR agonists and antagonists in the treatment of TAO.
3.11. Radiotherapy
Radiotherapy (RT) is a treatment option in TAO because of its non-specific anti-inflammatory
and specific immunosuppressive effects (lymphocytes infiltrating the orbital space are highly
radiosensitive) [219]. Moreover RT reduces GAG production by orbital fibroblasts [220]. RT
has especially benefical effects on soft tissue changes and optic neuropathy. Unfortunately, in
longstanding TAO, the benefical effects for reduction in proptosis and the improvement in
ocular motility are not satisfactory [90]. A systematic review and meta-analysis of eight
randomized controlled trials showed that, in patients with moderate to severe TAO, RT 20 Gy
is a valid therapeutic option which improves lots of ocular symptoms. According to medical
literature the dose of 20 Gy can be considered the optimal dose for orbital RT of TAO. The
cumulative dose is usually fractionated in 10 daily doses over a 2-week period to reduce the
cataractogenic effect [221]. Higher cumulative doses of RT does not improve the effectiveness
of treatment [222]. Combined use of GCs and orbital RT was found to be more effective than
using either one alone (140). Orbital RT is usually well tolerated. It may be associated with a
transient exacerbation of inflammatory eye signs and symptoms, but this is unlikely to occur
if GCs are concomitantly administered. Cataract is a possible complication of irradiation to the
lens. Radiation retinopathy is an extremely rare complication of RT. Systemic microvascular
disease due to diabetes mellitus (DM) or to previous chemotherapy may increase the risk for
radiation retinopathy [221].
A major concern about orbital RT is carcinogenecity. In a small cohort of patients treated with
RT for  TAO, there  was no significant  evidence of  radiation-induced cancer  death [224].
Wakelkamp et al. evaluated the frequency of long-term complications of orbital RT for TAO
(radiation-induced tumors, cataract, and retinopathy) in comparison with GCs. Mortality has
obtained similarly in the irradiated and nonirradiated patients [225]. Haenssle et al. reported
pigmented basal cell carcinomas 15 years after orbital RT therapy for TAO [226]. The long-
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term treatment results seem to be satisfactory. But long-term follow up studies with greater
numbers of patients are necessary to examine the risks and benefits more precisely. Orbital
radiotherapy, when properly performed, appears to be a safe procedure with limited side effects.
3.12. Plasmapheresis
In the first report by Dandona et al., a patient with Graves's disease with acute progressive
exophthalmos was treated with plasmapheresis. Their results has suggested that plasmaphe‐
resis could be a useful treatment option in acute and rapidly progressive ophthalmopathy
[227]. Glinoer et al. observed significant clinical improvement immediately after plasmaphe‐
resis. The most significant effects were on soft tissue involvement, proptosis, intraocular
pressure, and visual acuity [228]. In contrast to these, unfavorable effects of plasmapheresis
have been reported [229,230]. Trials involving plasmapheresis provided conflicting results.
We need RCTs to assess the efficacy and safety of plasmapharesis.
3.13. Total thyroid ablation
According to "shared" antigen(s) theory hypothesis; autoreactive T-lymphocytes which can
recognize and interact with one or more antigens shared by the thyroid and the orbital tissue,
trigger the event [231]. If this hypothesis is correct, in patients with appropriate genetic
background and exposed to relevant environmental risk factors, the presence of thyroid tissue
could be related with the development and progression of the ophthalmopathy [232,233]. A
progressive decrease and disappearance of circulating auto-antibodies in initially antibody-
positive thyroid cancer patients was demonstrated. This observation supports the theory that
total thyroid ablation reduces thyroid autoimmunity [234]. Spinelli et al. reported major
efficacy in the ophthalmopathy by total thyroidectomy(TT) [235]. De Bellis et al. evaluated the
effect of TT alone or followed by post-surgical 131Iodine with respect to methimazole treatment
on the activity and severity of TAO. Patients in TT and 131Iodine showed an early significant
decrease and a further progressive reduction of the activity and severity of TAO during the
follow-up, without statistically significant differences. These studies suggest that TT alone
could be an appropriate alternative to improve TAO with a reduction of the cost/benefit ratio
[236]. In conclusion, Total Thyroid Ablation (TTA) could be a possible treatment strategy for
TAO. Its advantages are; better outcomes in the short term and a shorter period for the
improvement of TAO. Because of its costs and risks TTA can not be recommended as a first-
line treatment option in TAO.
3.14. Surgical therapy
Orbital decompression
The goal of orbital decompression is to provide increased space for the increased orbital tissue,
by removing the bony or fatty components of the orbit. In this way it is effective on proptosis
and on the other ocular manifestations. This treatment could not act on the pathogenesis of
the diesease. Several techniques have been used to remove portions of one to four walls of the
orbit. The decision for which surgical techniques could be used, depends on the experience of
the orbit surgeon and the clinical situation of the patient [237].
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The studies in the medical literature could not make any meaningful comparisons between
the surgical techniques. In the previous studies because of the risks of surgery, orbital
decompression has been used in patients with marked proptosis and optic nerve compression,
especially if no beneficial effect was obtained with other treatments. But in recent years the
indications of orbital decompression has expanded. Garrity et al. reviewed the records of 428
consecutive eye surgery patients at the Mayo Clinic. These were; optic neuropathy, severe
orbital inflammation, proptosis, and glucocorticoid side effects [238]. According to the
EUGOGO consensus statement on TAO; orbital decompression for exophthalmos (rehabilita‐
tive surgery) could be delayed for at least 6 months, until the orbitopathy has been inactive
for a period, because surgery yields the best results when TAO is inactive. But in patients with
TAO who are intolerant or non-responsive to GCs, orbital decompression can be considered
in the active phase. In conclusion, orbital decompression seems to be an effective and safe
treatment for patients with TAO [116].
3.15. Medical and surgical recommendations
Bartalena et al. within the EUGOGO consensus statement on TAO, published the set of medical
and surgical recommendations shown in Figure 2.
All patients with TAO
Restore euthyroidism ,urge smoking withdrawal,
refer to specialist centers (except for the mildest cases)
local mesures
Mild Moderate to severe Sight-threatening (DON)
Local measures
wait and see
Stable and
inactive
Rehabilitive 
surgery
(if needed)
Progression Active İnactive
I.V GCS
(±OR)
Stable and
inactive
Rehabilitive 
surgery
I.V GCS
Poor response (2 weeks)
Prompt decompression
Stable 
and
inactive
Still active
I.V GCS
(±OR) Rehabilitive 
surgery
Commentary: Rehabilitative surgery includes orbital decompression, squint surgery, lid lengthening, and blepharo‐
plasty/browplasty. I.V.GCs: intravenous glucocorticoids; OR: orbital radiotherapy; DON: dysthyroid optic neuropathy.
Figure 2. Management of Thyroid-Associated Oophthalmopathy (TAO)
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4. Hyperthyroidism and bone
In 1891 Von Recklinghausen firstly described reduced bone mass in untreated hyperthyroid‐
ism. Thyroid hormones (3,3',5-triiodothyronine [T3] and 3,3',5,5'-tetra iodothyronine [T4]) act
on normal bone growth, development and turnover in both children and adults [239,240].
Hyperthyroidism increases bone turnover, acting mainly on bone resorption, but also on
osteoblast activity [241,242] [Figure-3]. As a result, hyperthyroidism is an important etiology
of secondary osteoporosis [243].
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Figure 3. Trabecular Bone Remoelling Cycle in (a) Hyperthyroid and (b) Normal Subjects
4.1. Mechanism
Direct stimulation of thyroid hormones on bone resorption in organ cultures have been
demonstrated [244]. This action may be mediated by a nuclear T3 receptor [245,246]. Thyroid
hormones may also affect bone calcium metabolism by a direct action on osteoclasts [247].
Besides the hormones of calcium metabolism, locally produced factors are important in
maintaining normal bone metabolism. Serum interleukin-6 (IL-6) concentration increases in
hyperthyroid patients and stimulates osteoclast production. Therefore, IL-6 may be an effector
of the action of PTH on bone [248]. Thyroid hormones may influence the IGF-I/IGFBP system
in vivo in hyperthyroidism. The anabolic effects of increased levels of IGF-I may be limited in
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hyperthyroidism due to the increases of inhibitory IGFBPs that can counteract the anabolic
effects and contribute to the observed net bone loss [249]. T3 activates fibroblast growth factor
receptor-1 (FGFR1) in bone and this can be related with the pathogenesis of skeletal disorders
resulting from thyroid disease [250].
4.2. Changes in hyperthyroidism
Histological changes in hyperthyroidism
Thyroid hormones increase the activation of new remodeling cycles. These effects include
predominantly increased osteoclastic activity. Although; excess osteoblastic activity, osteoid
deposition (osteomalacia) and rarefaction (osteoporosis) were also described. These changes
were observed both in trabecular and cortical bone ([51]. In 1978 Mosekilde & Melsen dem‐
onstrated a unique histomorphometric pattern; with evidence of both increased osteoblast and
osteoclast activity in hyperthyroidism. These changes have given rise to a net loss of bone
volume and were evident in both cortical and trabecular bone. But cortical bone has been rather
more influenced (Figure-4) [252]. An in-vitro organ culture of fetal rat bone, demonstrated a
direct stimulation of bone resorption by prolonged treatment with T4 or T3 [244].
Biochemical changes in hyperthyroidism
a. Calcium homeostasis in hyperthyroidism
The majority of patients with hyperthyroidism have normal or near normal total serum
calcium levels. However, ionized serum calcium levels are elevated in most of the patients.
Changes in serum calcium levels correlate with serum T3 levels [253,254]. Generally hyper‐
calcemia in hyperthyroidism tends to be mild or asymptomatic. Severe (>15 mg/dl) and
symptomatic hypercalcemia is rare [255]. Hypercalcemia usually resolves after attainment of
euthyroid state by all therapeutic modalities, i.e. subtotal thyroid resection, antithyroid drugs
and radioiodine therapy. Symptomatic hypercalcemia can be treated by rehydration, use of
corticosteroids, calcitonin and phosphate therapy. Reduced renal tubular and intestinal
calcium reabsorption leads to increased urinary and fecal calcium [241]. The hyperadrenergic
state of hyperthyroidism contributes hypercalcemia [256]. These changes correlate positively
with thyroid hormone levels and cortical osteoclastic activity. Hypercalcemia in hyperthyr‐
oidism is unrelated to the parathyroid hormone (PTH) levels [253,254].
b. Phosphorous homeostasis in hyperthyroidism
Most of the patients have increased serum phosphorous levels. But some studies have shown
normal or low levels of serum phosphorous. Increased bone and tissue catabolisms which lead
to excess input of phosphorous to the plasma, lower clearance and increased renal tubular
reabsorption of phosphorous may lead to hyperphosphatemia in hyperthyroidism. These
changes are related to suppressed PTH levels and direct effects of thyroid hormones. Antithy‐
roid treatment normalizes serum phosphorous concentration [253].
c. Parathyroid hormone secretion in hyperthyroidism
The reduction of serum PTH levels has been reported for the first time by Bouillon and DeMoor
[257]. This observation confirmed by other clinical trials. Increased serum calcium levels inhibit
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PTH secretion, so there is an inverse relationship between serum PTH and calcium levels.
Additionally, serum parathyroid hormone-related peptide (PTH-rP) levels increase in
hyperthyroidism. In hyperthyroid patients, a significant elevation in PTH-rP levels was
obtained when compared with healthy controls. After treatment, levels of PTH-rP declined.
PTH-rP could be a factor in the pathogenesis of hypercalcemia in hyperthyroid patients [258].
d. Vitamin D in hyperthyroidism
Serum concentrations of 25-hydroxyvitamin D3 (25(OH)D3)and 1,25-dihydroxyvitamin D3
(1,25(OH)2D3) in hyperthyroidism have been evaluated in many clinical trials. In most studies,
serum 25(OH)D3 levels were normal [255,259]. However, few studies in medical literature
obtained lower serum 25(OH)D3 levels in patients with hyperthyroidism than control subjects
[260,261]. Karsenty et al. found a higher metabolic clearance rate of 1,25(OH)2D3 in hyperthy‐
roid patients than in control subjects [262]. These changes in serum concentrations of
25(OH)D3 and 1,25(OH)2D3 are probably unrelated with the direct effects of thyroid hormones
on bone metabolism. It is postulated that lower levels of serum 25(OH)D3 and 1,25(OH)2D3,
can be related with reduced intestinal absorption [261]. Biochemical changes in hyperthyr‐
oidism are shown in Figure-2.
4.3. Evaluation of bone turnover in hyperthyroid patients and serum markers
Alkaline phosphatase (ALP)
Patients with hyperthyroidism have elevated levels of serum [263]. Total, liver, and bone
ALP activities obtained significantly higher in hyperthyroid patients. Bone ALP level are
more markedly elevated than liver ALP. Intestinal ALP does not differ significantly between
hyperthyroid and normal subjects. These changes correlate positively with thyroid hormone
levels. After a euthyroid state is achieved, serum ALP level remains elevated for a prolonged
time. This means increased bone turnover continues even after restoration of hyperthyroid‐
ism [264].
Other serum markers
Serum pyridinoline (PYD) and deoxypyridinoline (DPD) [265,266]., osteocalcin [267].,
carboxy-terminal propeptide of type 1 procollagen (P1CP) and carboxy-terminal telopeptide
of type 1 collagen (1CTP) [268]., serum bone Gla protein (BGP) [269]. and serum osteoprote‐
gerin (OPG) [270]. levels were obtained significantly higher in hyperthyroid patients than in
control subjects. These laboratory parameters can be considered as reliable non-invasive
markers of bone turnover in hyperthyroid patients. All markers were correlated with serum
thyroid function tests and were normalized after a eutyhyroid state was achieved.
4.4. Clinical implications
Hyperthyroidism causes reduction in bone mineral density (BMD) assessed by the measure‐
ment of lumbar vertebrae and femur by dual energy X-ray absorptiometry (DEXA) [271].
Hyperthyroidism affects bone mineralization especially during the early post-menopausal
period and the effect is mainly at the cortical bone [272]. However, hyperthyroidism could be
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associated with bone loss and may be a risk factor for the development of osteoporosis in pre-
menopausal women [273]. It has been well established that hyperthyroidism leads to reduced
BMD in female patients, but there is lack of acceptable data in male patients. Majima et al.
evaluated BMD and bone metabolism in male patients with hyperthyroidism. The study
demonstrated a high prevalence of cortical bone loss in male patients with hyperthyroidism,
especially in elderly patients [274].
Also, endogenous subclinical hyperthyroidism can be a risk factor for osteoporosis. In several
cross-sectional studies, BMD was decreased at multiple sites in pre-and post-menopausal
women with endogenous subclinical hyperthyroidism [275-277]. This finding, however, was
not confirmed in other cross-sectional observations in endogenous conditions [278]. Földes et
al. demonstrated that numbers of pre-menopausal patients with endogenous sub-clinical
hyperthyroidism BMD of the lumbar spine, femoral neck and the midshaft of the radius were
not significantly decreased. But in post-menopausal women with long-lasting endogenous
sub-clinical hyperthyroidism mean densitometric values were slightly, but significantly, lower
[279]. Whether endogenous sub-clinical hyperthyroidism significantly affects bone metabo‐
lism and increases the risk of fractures remains controversial.
Prolonged hyperthyroidism due to L-thyroxine(L-T4) treatment has been associated with
reduced bone mass and thus with the potential risk of premature development of osteoporosis.
The effects of L-T4 treatment have been evaluated in many clinical trials. In several studies,
bone mineral density was decreased at multiple sites in pre-and post-menopausal women
treated with L-T4 [280,281]. In a study by Giannini et al. post-menopausal thyroidectomized
patients showed significantly lower bone mass than pre-menopausal patients. A negative
correlation between time since menopause and bone mass were obtained in post-menopausal
L-T4 treated patients [282]. There is lack of acceptable data about the effects of L-T4 treatment
on bone metabolism in male patients. A mild deleterious effect of thyroid hormone excess in
the axial bone mass from male subjects obtained. Male patients with chronic TSH suppression
by L-T4 or history of hyperthyroidism should be assessed by BMD [283]. However, several
recent studies have failed to show such a harmful effect of L-T4 treatment on BMD [284-286].
It should be noted that other risk factors may affect BMD in hyperthyroid patients. These
include a relative deficiency of insulin-like growth factor type I, dehydroepiandrosterone
sulfate [287], vitamin D receptor (VDR) polymorphisms [288] and estrogen [289]. The question
as to whether prolonged hyperthyroidism due to L-T4 treatment increases the risk of fractures
also remains controversial.
4.5. Diagnosis
BMD measuring by DEXA scan is one of the best techniques to obtain the extent of bone
changes in hyperthyroidism. DEXA scan offers monitoring for response to therapy and with
little radiation it gives very reliable measurements [290]. Quantitative ultrasound (QUS) might
give information about bone mass and also on bone elasticity and structure. Advantages are
the lower expense, portability, and lack of radiation exposure [291]. Acotto et al. reported
significantly lower QUS parameters in hyperthyroid patients in comparison with controls
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[292]. For practical use, the development of quality standards and criteria for diagnosing
osteoporosis are necessary.
Prevention and treatment of reduced bone density
Patients with a history of hyperthyroidism and who are treated with L-T4 replacement/
supressive therapy should be considered at higher risk of reducing BMD and developing
clinically significant osteoporosis. These patients should be encouraged to modify other risk
factors for osteoporosis such as smoking, drinking excessive alcohol, low Ca+² intake and lack
of exercise [293]. In these patients adequate daily calcium intake should be provided. Kung et
al. found that 1,000 mg. daily calcium supplementation prevents bone loss in post-menopausal
women taking suppressive doses of L-T4 compared with a placebo [294]. Estrogen replacement
therapy prevents a decrease of BMD in postmenopausal women with previous hyperthyroid‐
ism and subsequent L-T4 therapy [295,296]. These potentially beneficial effects of estrogen
replacement on BMD in postmenopausal women with a history of thyroid disease suggests
that estrogen administration should be encouraged in this group.
U-Ca+²
U-PO4
PTH
Thyroid hormones
U-OHP
U-PYD /  DPD
ALP
Osteocalcin
Ca+² 
Faecal
Ca+²
PO4 Reduced
intestinal
absorption
25(OH)D3
1,25(OH)2D3 N /  
Abbreviations are as follows: calcium (Ca), alkaline phosphatase (ALP), 25 hydroxy vitamin D3 (25 OH D), 1,25 dihy‐
droxy vitamin D3 (1,25 (OH)2D3), 24,25 dihydroxy vitamin D3 (S-24,25 (OH)2D), parathyroid hormone (PTH), phosphate
(PO4), urinary calcium (U-Ca), urinary hydroxyproline (U-OHP), urinary phosphate (U-PO4), urinary pyridinium and de‐
oxypyrodinoline (U-PYD/DPD). (Data adapted from reference 292).
Figure 4. Biochemical Changes in Hyperthyroidism.
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Titration of suppressive therapy to maintain serum TSH concentration between a slightly low
(e.g. between 0.1-0.5 mU/l) range may prevent bone loss [297]. Guo et al demonstrated a
reduction of L-T4 dose in post-menopausal women with suppressed serum TSH levels related
with deceleration of bone turn over (serum osteocalcin and urinary excretion of bone collagen-
derived pyridinium cross-links decreased) and increased BMD (lumbar/femoral) [298]. Careful
titration of L-T4 dosage to maintain biochemical euthyroidism is the most important way to
prevent the adverse effect of T4 on bone.
The major question is whether the decrease in BMD caused by hyperthyroidism can be
reversible. Many clinical trials have obtained that there is some reversibilty of bone mass after
treatment of hyperthyroidism [293,299-301]. Another question is whether antiresorptive
treatment is effective on hyperthyroidism related osteoporosis. Two clinical trials evaluated
the increase of BMD in osteoporotic/osteopenic hyperthyroid patients treated with only anti-
thyroid drugs versus patients treated with anti-thyroid drugs and alendronate. The combina‐
tion of anti-thyroid drugs and alendronate was found to be more efficacious than anti-thyroid
therapy alone [302,303]. Majima et al. evaluated the efficacy of risedronate for the treatment
of osteoporosis/osteopenia in patients with Graves' disease. The percentage increases in BMD
at the lumbar spine and distal radius were significantly greater in patients treated with an anti-
thyroid drug and risedronate than treated with an anti-thyroid drug only [304]. These findings
conclude that bisphosphonates can be considered as a treatment option in decreased bone mass
cases associated with hyperthyroidism. Kung et al. demonstrated intranasal calcitonin with
calcium supplements was not more effective than calcium supplements alone in preventing
bone loss induced by thyroxine suppressive therapy in post-menopausal women [305]. Jódar
et al. designed a prospective study to evaluate the effects of antiresorptive therapy with nasal
salmon calcitonin (CT) in hyperthyroid patients receiving standard medical treatment. They
showed that treatment with nasal CT has no additional beneficial effect compared with the
attainment of the euthyroid state [306]. But in another study by Akçay et al. the addition of
intranasal calcitonin to the anti-thyroid drugs was found to be effective in preventing the
degradation of bone [307]. More prospective, randomized and controlled trials, which include
large series of patients, are required to obtain more accurate results about antiresorptive
treatment in hyperthyroidism.
5. Thyroid storm
Thyroid storm (TS) [thyrotoxic crisis] is an uncommon, life-threatening condition reflecting
the augmentation of the manifestations of thyrotoxicosis. Mortality rates are high (10-20%) and
occur in less than 10% of patients hospitalized for thyrotoxicosis. TS occurs nine to ten times
more commonly in women than in men, and the most common aetiology is Graves’ hyper‐
thyroidism. However, any aetiology of thyrotoxicosis can cause TS. This situation can be
precipitated by a number of factors shown in Table-3 [308-312].
The pathophysiology of thyroid storm is not fully understood. The current theory is that;
increased numbers of catecholaminergic receptors being exposed to increased catecholamine
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levels in states of stress. Decreased binding to thyroxine-binding globulin (TBG), markedly
increase in free thyroid hormone levels may also play an important role [313].
∙ Severe infections (pulmonary) ∙ Direct trauma or surgical manipulation of the thyroid gland
∙ Diabetic ketoacidosis (DKA) ∙ Biological agents such as interleukin-2 and α-interferon
∙ Surgery ∙ Discontinuation of anti-thyroid medications or poor patient
adherence to the treatment
∙ Trauma ∙ Cerebrovascular disease
∙ Pulmonary thrombo-embolism ∙ Myocardial infarction (MI)
∙ Salicylates * ∙ Exogenous thyroid hormone intake
∙ Administration of large quantities of exogenous
iodine **
∙ Pregnancy
∙ Radioactive iodine therapy ∙ Unknown factors
*They increase the concentration of circulating free thyroid hormones to critical levels
**Such as iodinated contrast agents or amiodarone
Table 3. Precipitating Factors for Thyroid Storm
Clinical presentation of thyroid storm
Symptoms of thyroid storm are similar to those of hyperthyroidism, but they are more sudden,
severe and extreme. The main findings are high fever (38-41° C) accompanied by excessive
sweating and flushing. Other common symptoms include; altered mental status (confusion,
agitation, overt psychosis, and in extreme cases, even coma), cardiovascular complications
[tachycardia, cardiac arrhythmias (including atrial fibrillation), high systolic bood pressure,
low diastolic bood pressure and congestive heart failure], diffuse muscle weakness, tremor or
fasciculations and neuropsychiatric syndromes. Gastrointestinal involvement presents with
nausea, vomiting, diarrhoea and abdominal pain. Liver dysfunction (cardiac failure with
hepatic congestion or hypoperfusion, direct effect of the excess thyroid hormones) could be
present with jaundice [309,314]. Elderly patients often present with apathy, stupor, cardiac
failure, coma and minimal signs of thyrotoxicosis so-called apathetic thyroid storm [313].
The scoring system suggested by Burch and Wartofsky (Table 4) illustrates the typical features
of thyroid storm [315]. The clinical symptomatology is sometimes difficult to distinguish from
other medical emergencies [308]. Differential diagnosis of TS is shown in Table-5.
5.1. Diagnosis
Diagnosis depends on primarily clinical findings. There are no specific laboratory tests
available. Serum thyroid hormone levels (i.e. free T3 [FT3] and free T4 [FT4]) are elevated with
suppressed TSH levels (with the rare exceptions being states of thyroid hormone resistance or
TSH secreting pituitary adenomas). An immediate search should begin for precipitating
factors. Pregnancy should be excluded urgently in any woman of childbearing age with
urinary or plasma assessment of human chorionic gonadotropin (HCG) levels. Routine
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Clinical feature Scoring points
1. Thermoregulatory dysfunction
Temperature °F (°C)
99-99.9 (37.2-37.7) 5
100-100.9 (37.8-38.2) 10
101-101.9 (38.3-38.8) 15
102-102.9 (38.9-39.4) 20
103-103.9 (39.5-39.9) 25
≥104 (40) 30
2. Cardiovascular dysfunction
∙ Tachycardia (beats per minute)
<99 0
99-109 5
110-119 10
120-129 15
130-139 20
≥140 25
∙ Congestive heart failure
Absent 0
Mild (Pedal oedema) 5
Moderate (Bibasal rales or crackles) 10
Severe (Pulmonary oedema) 15
∙ Atrial fibrillation
Absent 0
Present 10
3. Central nervous system dysfunction
Absent 0
Mild (Agitation) 10
Moderate (Delirium, psychosis, extreme lethargy) 20
Severe (Seizures, coma) 30
4. Gastrointestinal-hepatic dysfunction
Absent 0
Moderate (Diarrhoea, nausea/vomiting, abdominal pain) 10
Severe (Jaundice) 20
5. Previous episode of thyroid storm
Absent 0
Present 10
TOTAL
>45 Highly likely thyroid storm
25-44 Suggestive of impending storm
<25 Unlikely to represent storm
Table 4. Diagnostic Criteria for Thyroid Storm
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biochemical tests, urinalysis, urine sediment, complete blood count, chest X-ray and related
cultures should be made, to exclude infectious diseases. Electrocardiography (ECG) and
cardiac enzymes should be procured, to exclude arrhythmia and myocardial infarction (MI)
[313]. Leukocytosis, increased transaminase-bilirubin levels, hypoglycemia and lactic acidosis
can be seen in laboratory evaluation [316,317].
Neurolept malignant syndrome Hypertensive encephalopathy
Malignant hyperthermia Alcohol withdrawal
Phaeochromocytoma Benzodiazepine / barbiturate withdrawal
Hypoglycemia Opioid withdrawal
Hypoxia Heat stroke
Sepsis Encephalitis / meningitis
Table 5. Differential Diagnosis of Thyroid Storm
5.2. Management
The patient should be managed in an intensive care unit. ABCDEs (i.e. airway; breathing;
circulation; disability, i.e. conscious level; and examination) should be provided as soon as
possible. Precipitant factors such as infection, trauma, MI, DKA, and other underlying
processes should be managed as per standard care [313].
General supportive care
First of all haemodynamic stability should be provided. Supportive care includes cooling
measures, intravenous (IV) fluid-electrolyte replacement and nutritional support. In order to
control profound pyrexia cooling blankets and acetaminophen can be used. Salicylates should
be avoided (increase the concentration of circulating free thyroid hormones). Tachyarrhyth‐
mias, which cause haemodynamic instability should be managed with cardioversion by
defibrillation. Otherwise, tachyarrhythmias can be managed with appropriate anti-arrhythmic
therapy. Diuretics, ACE inhibitors and digitalis can be used carefully for heart failure. Based
on arterial blood gas (ABG) analysis and other assessments; ventilatory support, either with
non-invasive positive pressure ventilation (NIPPV) or intubated ventilation, could be per‐
formed. In patients with severe agitation, medical intervention could be difficult. Sedatives
such as haloperidol or a benzodiazepine can be used in this situation. Phenobarbital increases
peripheral metabolism and inactivation of FT3-FT4. Chlorpromazine has the additional benefit
of reducing body temperature through effects on central thermoregulation. However, these
agents should be monitored for respiratory side effects. Nutritional support is important. This
includes vitamin (e.g. thiamine) and glucose replacement (as liver glycogen stores are depleted
during a thyroid storm) [313].
Thyroid-specific therapy
Thyriod-specific therapy includes; decreasing thyroid hormone synthesis, prevention of
thyroid hormone release and decreasing peripheral action of circulating thyroid hormones
[318]. In the treatment of thyroid storm, the five B’s should be kept in mind. This includes ‘Bs’:
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Block synthesis (i.e. antithyroid drugs); Block release (i.e. iodine); Block T4 into T3 conversion
(i.e. highdose propylthiouracil [PTU], propranolol, corticosteroid and, rarely, amiodarone);
Betablocker; and Block enterohepatic circulation (i.e. cholestyramine) [313].
Anti-thyroid drugs include PTU or carbimazole (or methimazole). PTU was preferred because
of its more rapid onset of action, short half-life and inhibition of peripheral deiodinase enzyme-
mediated conversion of T4 into T3. PTU could be administered orally or via a nasogastric (NG)
tube, if the patient is not suitable for oral administration, both PTU and methimazole can be
given as a rectal suppository or enema. PTU is administered with a loading dose of 600mg
followed by a dose of 200-250 mg every 4-6 hours. Carbimazole (or methimazole) is adminis‐
tered at a dose of 20-30mg every 4-6 hours [318]. The major concern about PTU is hepatoxicity.
In the thyroid storm management, there are not any comparative trials showing superiority
of PTU over either carbimazole or methimazole. It’s now recommended that using either
carbimazole or methimazole in thyroid storm (unless there is a contra-indication such as
pregnancy), and achieving T4 into T3 conversion inhibition just with beta-blockers and
corticosteroids [319].
Iodine should be administered at least 1 hour after PTU or carbimazole (or methimazole)
administration. In this way undesired tyrosine residue iodination and enrichment of thyroid
hormone stores could be prevented. Iodine could be administered in various formulations
(Table-6) [313].
In order to block the adrenergic effects of thyroid hormones betablockers should be adminis‐
tered immediately. A non-cardiac specific betablocker; propranolol can be used for this
purpose. Propranolol has the advantages of being suitable for IV administration and of
inhibition of peripheral T4-T3 conversion at high doses. Decompensated cardiac function,
triggered with tachycardia, can be treated with beta-blockers. However, beta-blockers should
be used with caution in patients with a history of heart failure. Cardioselective beta-blockers
such as metoprolol or atenolol could be used in patients with asthma and chronic obstructive
pulmonary disease, which are contra-indications for non-cardiac specific betablockers. If
unfavorable cardiac effects are expected, a short-acting beta-blocker; esmolol, can be used as
an alternative drug. Diltiazem, a calcium-channel blocker, can be used when there is absolute
contra-indication for beta-blockers (Table-6) [313].
Thyroid hormones accelerate cortisol metabolism and may trigger an adrenal crisis. Thyroid
crisis give rise to low plasma levels of ACTH and cortisol. Therefore, against a possible adrenal
insufficiency, exogenous corticosteroid therapy should be administered [320]. Furthermore,
corticosteroids inhibit peripheral conversion of T4 into T3 and have been shown to improve
outcomes in patients with thyroid storm [318]. Hydrocortisone or an equivalent corticosteroid
can be used for this purpose (Table-6). Then, the treatment should be withdrawn gradually,
based on the required duration of steroid therapy.
Other possible treatment options are lithium carbonate, potassium perchlorate and cholestyr‐
amine. Lithium inhibits thyroid hormone release from the gland and reduces iodination of
tyrosine residues. Lithium carbonate can be an alternative treatment option when there is a
contraindication or previous toxicity history to thionamide therapy. The major concern about
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lithium carbonate is it’s toxicity. Potassium perchlorat inhibits iodide transport into the
thyrocyte [313]. Erdogan et al. demonstrated that the combination of thionamides, corticoste‐
roids and potassium perchlorat for a short period could be effective in the treatment of
amiodarone-induced thyrotoxicosis [321]. The most important side effects of potassium
perchlorat are aplastic anaemia and nephritic syndrome. To inhibit the enterohepatic circula‐
tion of thyroid hormones, a T4 and T3 binding resin, cholestyramine can be used [322].
Emerging treatments
In spite of all treatment approaches, clinical improvement could not be obtained. In this
situation, different treatment approaches can be tried in order to remove thyroid hormones
from the circulation.
Plasmapheresis should be considered as a treatment option, especially when patients have
failed or cannot tolerate conventional therapy. Plasmapheresis leads to amelioration of
symptoms and a significant decline in thyroid hormone levels, providing a window to treat
definitively with thyroidectomy [323,324]. In each session only small amounts of thyroid
hormones can be removed from the circulation, therefore plasmapharesis can be repeated.
Koball et al. reported a case of thyrotoxic crisis treated with plasmapheresis and single pass
albumin dialysis. Thyroxine can be bound by albumin and removed by extracorporeal single-
pass albumin dialysis (SPAD). The patient underwent two sessions of plasmapheresis without
clinical response. After four SPAD treatments clinical status of the patient improved. Accord‐
ing to this report SPAD represents a safe and efficient alternative to plasmapheresis [325].
Charcoal haemoperfusion has also been demonstrated to be effective in thyrotoxic states [326].
6. Thyrotoxic hypokalaemic periodic paralysis
Hyperthyroidism can be related with muscular disorders such as acute and chronic thyrotoxic
myopathies, exophthalmic ophthalmoplegia, myasthenia gravis, and periodic paralysis [327].
The association between thyrotoxicosis and periodic paralysis was first described by Rosenfeld
in 1902. Thyrotoxic hypokalaemic periodic paralysis (THPP) is a rare condition which occurs
in 2% of patients with thyrotoxicosis. THPP is generally sporadic, but autosomal recessive or
autosomal dominant cases have been reported and may be associated with certain HLA
haplotypes [HLA-Bw46 / B5 / DRw8 / CW7] [328-330]. THPP has been reported in many ethnic
groups such as Asian populations and Caucasians [331]. THPP appears almost exclusively
(85%) in young men between the ages of 20-39 [327].
Many aetiological factors that can lead to hyperthyroidism may be associated with THPP. It
has been reported that the most important aetiologic factor is Graves’ disease according to
large case series [332,333]. Other possible aetiological factors are subacute thyroiditis, silent
thyroiditis [334], autonomously functioning thyroid nodules [335], thyrotropin-secreting
pituitary adenomas [336,337], ingestion of excessive thyroxine [338], thyroxine-containing
herbal and dietary supplements [339], iodine induced thyrotoxicosis with inadvertent use of
iodine or with drugs containing iodine such as iodinate contrast agents or amiodarone
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Medication Dose Notes
Inhibition of hormone synthesis
Propylthiouracil (PTU) 600mg loading dose, followed by200-250mg PO q4-6h
Additional inhibition of
peripheraldeiodination However,
recent warning from FDA regarding
severe liver toxicity with PTU makes
either carbimazole or methimazole
first-choice thionamide
Carbimazole (or methimazole) 20-30mg PO q4-6h
Inhibition of hormone release
Potassium Iodide 5 drops PO q6-8h Administer at least 1 hourafter thionamide
Lugol’s Solution 5-10 drops PO q6-8h Administer at least 1 hourafter thionamide
Iapanoic Acid 1000mg IV q8h for 24 h, followed by500mg bd
Administer at least 1 hour after
thionamide, infrequently available
Inhibition of peripheral effects of excess thyroid hormone
Propranolol 1-2 mg/min IV q15min up tomax 10mg 40-80mg PO q4-6h
IV dose initially if haemodynamically
unstable
Esmolol
50 mg/kg/min IV -may increase by
50 mg/kg/min q4min as required to a
max of 300 mg/kg/min.
Short acting
Metoprolol 100mg PO q6h Cardioselective; use if known airwaysdisease
Diltiazem 60-90mg PO q6-8h Use if beta-blockers contraindicated IVformulation available
Supplementary management
Hydrocortisone 100mg IV q6h
Dexamethasone 2mg IV q6h Care if significant hepatic dysfunction
Acetaminophen 1 g PO q6h
Additional therapies
Lithium Carbonate Carbonate 300mg PO q8h Monitor for toxicity
Potassium perchlorate 1 g PO od Associated with aplastic anaemia
Cholestyramine 4 g PO q6-12h and nephritic syndrome
PO, oral; IV, intravenous; q4-6h, every 4_6 hours; q6h, every 6 hours; q8h, every 8 hours; q4min, every 4 minutes; q15min,
every 15 minutes;od, once daily; bd, twice daily.
(Data adapted from reference 313)
Table 6. Medical Management of Thyroid Storm
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[340,341], interferon-alpha-induced thyrotoxicosis [342] and radioactive iodine therapy
induced radiation thyroiditis [343]. Many precipitating factors can trigger THPP attacks
(Table-7) [344-346].
Carbohydrate-rich meal
Strenuous exercise
Awakening in the middle of sleep
Emotional stres
Radioactive iodine treatment
Menses
Epinephrine
Cold
Alcohol
Glucocorticoids
Injection of medicine
Upper respiratory tract infection
Trauma
Insulin
Table 7. Precipitating factors
The pathophysiology of THPP is not certain. However, it can be explained by some mecha‐
nisms (Figure-5). A quick shift of potassium from the extracellular compartment to the
intracellular compartment causes hypokalemia. This especially occurs in the muscles. Excess
thyroid hormone and insulin levels, increased sensitivity of beta-receptors to catecholamines
in thyrotoxicosis causes an increase in sodium/potassium-adenosine triphosphatase (Na/K-
ATPase) pump activity [347,348]. This mechanism explains insulin and epinephrine induced
paralytic attacks. Factors related with an increased insulin and epinephrine levels, such as
carbohydrate rich meals, emotional stress, cold, trauma and infection trigger THPP. During
exercise K releases from the skeletal muscles, but in the resting process K again returns to the
intracellular compartment. Because of this transport of the potassium, periodic and paralytic
attacks usually occur during resting time [349].
6.1. Clinical features
THPP attacks mostly occur in the late night or early morning and last from a few hours
up to several days. Prodromal symptoms such as aches, cramps and stiffness can be seen
[334]. The typical motor involvement in THPP begins from the lower limbs and ascends to
the upper limbs. The muscles affected may be asymmetrical. The severity of attacks range
from mild weakness to flaccid paralysis. Clinical improvement starts from the most recently
affected muscles. Sensory function is not affected and deterioration of mental functions has
never been seen [327]. Paralysis of respiratory, bulbar, and ocular muscles has been rarely
reported in severe attacks of THPP. Respiratory muscle involvement can be fatal [350]. Deep
tendon reflexes are markedly diminished or absent. Patients completely recover between
the attacks [348].
6.2. Laboratory features
The cardinal laboratory finding in THPP is hypokalaemia. But normokalaemic TPP have been
reported in some cases [351,352]. Severe hypokalaemia may trigger life-threatening arrhyth‐
mias and the severity of paralysis correlates with the degree of hypokalemia but not with the
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thyroid hormone level. Therefore the degree of hypokalaemia is important [353,354]. Hypo‐
phosphataemia and hypomagnesaemia could be obtained in THPP [332]. Hypokalemia can
cause vasoconstriction in muscle arterioles and may lead to ischemic changes in sarcolemma.
Thus hypokalaemia causes rhabdomyolysis [355]. Besides hypokalaemia, hypophosphatae‐
mia [356] and hyperthyroidism alone may cause rhabdomyolysis [357]. As a result of rhabdo‐
myolysis, serum creatine phosphokinase (CPK) level increases [332,358]. ECG changes in
THPP vary from nondiagnostic to those showing typical features of hypokalaemia and serious
ventricular arrhythmias. Other possible ECG changes include rapid heart rate, high QRS
voltage, and first-degree atrioventricular block [359,360].
6.3. Management
In cases of acute attacks of THPP immediate restoration and close monitoring of serum
potassium is important. Potassium replacement can be done in two ways; oral or intravenous.
Intravenous potassium has significant superiority to the oral route in the improvement of the
clinical findings and it is the major choice if the patient shows signs of cardiac dysrhythmia,
respiratory distress or is unable to take oral medications. Potassium replacement should not
exceed 90 mEq/24h because of the possibility of rebound hyperkalemia [327,344,361]. A non-
selective beta-blocker, propranolol, increases serum potassium and phosphate concentrations
and ameliorates paralysis [362].
THPP does not disappear completely unless patients become euthyroid. Thus, the manage‐
ment of hyperthyroidism is the mainstay of therapy. Permanent treatment is so important and
could be done by antithyroid drugs, radioiodine therapy or surgery [348]. Although gluco‐
corticoids (GCs) have been used to treat hyperthyroidism, they have detrimental effects on
insulin sensitivity. Thus GCs can mimic this physiologic process and induce attacks. Physicians
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should be aware of the risk of triggering THPP when using high-dose GCs in the thyrotoxic
phase [363]. To prevent recurrence of attacks, precipitating factors should be avoided.
The use of propranolol is important during early treatment with anti-thyroid drugs or after
radioactive iodine when the euthyroid status is not yet achieved. Propranolol also reduces the
frequency and severity of attacks. If the patient's serum potassium level is between normal
ranges, prophylactic potassium supplementation is not effective to prevent the attacks.
Acetazolamide may worsen the attacks in THPP and should be avoided [364,365].
7. Thyrotoxicosis related psychosis and convulsion
7.1. Hyperthyroidism and central nervous system
The brain, particularly the limbic system (amygdala and hippocampus), has a large number
of Tri-iodothyronine (T3) receptors. These receptors affect a variety of functions such as
emotion, behavior, and long term memory [366]. Excess thyroid hormones affect neurotrans‐
mitters such as serotonin, dopamine, or second messengers. This could be a possible explan‐
ation for the relation between neuropsychiatric symptoms and hyperthyroidism [367].
Evidence suggests that the modulation of the beta-adrenergic receptor response to catechola‐
mines in the central nervous system by thyroid hormones in thyrotoxic patients, may contrib‐
ute to psychotic behavior [368].
As a result, people with thyroid dysfunction could be presented with a wide variety of
neuropsychiatric symptoms such as anxiety, irritability, unstable mood, fatigue, insomnia,
dementia, confusion state, depression, thyrotoxic crisis, seizures, pyramidal signs, chorea,
attention deficit-hyperactivity disorder, sleepwalking (somnambulism)and Hashimoto's
encephalopathy. “Apathetic thyrotoxicosis” is an unusual presentation of hyperthyroidism,
characterised by depression, psychomotor slowing and apathy and occurring mostly in the
elderly [369-371].
7.2. Psychosis
More than 150 years ago, von Basedow first described a psychotic illness, probably mania, in
a patient with exophthalmic goitre [372]. More recent case reports have emphasised depressive
[373], manic [374], paranoid [375] and schizophreniform features [372]. But psychotic reactions
as the presenting feature of thyrotoxicosis is extremely rare, it was reported in 1% of cases and
most patients who develop psychosis have been previously diagnosed with mania and/or
delirium [376]. The occurrence of psychosis depends on the severity and duration of thyroid
disease and the underlying predisposition of the individual to psychiatric instability [377].
Most of the cases caused by thyrotoxicosis or hyperthyroidism have been described in patients
with Graves’ disease or toxic multinodular goiter. Therefore, transient thyroiditis or factitious
thyrotoxicosis can be related with neuropsychiatric symptoms, including organic psychosis
[378]. Only one case each of postpartum thyroiditis [379] and subacute thyroiditis [377] have
Thyroid Disorders - Focus on Hyperthyroidism100
been reported related with psychosis. The relations between thyroid autoimmunity and
anxiety disorders have been reported [380].
But it should be noted that psychiatric disorders can trigger hyperthyroxinemia [381].
Differential diagnosis between the two conditions is important. In such cases the TSH level is
usually in the upper “normal” range and free thyroxine elevation is modest and transient and
is usually seen within 1 week. This entity has not been established clearly, but may be
considered a form of non-thyroidal illness [382].
7.3. Management
Treatment of hyperthyroidism by standard anti-thyroid drugs (propylthiouracil, methima‐
zole, carbimazole) results with improvement in mental and cognitive symptoms. Psychiatric
improvements parallel with improvements in endocrine symptoms. Trzepacz et a.l also
showed that a similar improvement both in psychiatric and endocrine symptoms by two weeks
of propranolol treatment could be obtained [383,384].
Because of their slow onset of action and potential toxicity, psychotropic drugs (lithium,
benzodiazepines, antidepressants and antipsychotics) are not recommended as the primary
treatment option for neuropsychiatric symptoms caused by hyperthyroidism. Dopamine
receptor blockade with an antipsychotic such as haloperidol can be used in patients with severe
neuropsychiatric symptoms. If there is an exhibited psychiatric disease before hyperthyroid‐
ism, β-adrenoceptor antagonists may not be effective and neuropsychiatric symptoms may
remain after euthyroidism has been achieved, in which case psychotropic drug treatment
should be given. Selective serotonin reuptake inhibitors, lithium and benzodiazepines can be
used for the treatment of neuropsychiatric symptoms [366].
If therapy fails with the above-mentioned options, more radical approaches such as radioactive
iodine ablation and thyroidectomy should be considered [377,385].
7.4. Convulsion
Seizures in hyperthyroidism have rarely been reported in medical literature. Most of the cases
were related with Graves’ hyperthyroidism [386-388]. Other aetiologic factors were massive
levothyroxine ingestion [389], L-thyroxine treatment for hypothyroidism [390,391], subclinical
hyperthyroidism [392] and Hashimoto’s encephalopathy (HE) [393,394]. The pathophysiology
of HE is not clear but increased antithyroid antibodies in all affected patients supports an
autoimmune etiology. Generally, patients in medical literaure were euthyroid or hypothyroid.
But Sakurai et al reported a case of HE associated with Basedow's disease presented with
hyperthyroidism. Another possible aetiologic factor for seizures in hyperthyroidism may be
superior sagittal sinus (SSS) thrombosis. Hyperthyroidism may cause hypercoagulabilty,
venous stasis and could be related with thrombosis. All cases of seizures in SSS thrombosis in
medical literature were known cases of hyperthyroidism [395-397].
The certain incidence of seizures in hyperthyroidism is still unknown. Song et al. recently
informed a 0.2% prevelance in a retrospective study [398]. Seizures were seen more frequent
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in women than in men, but no differences in the pattern of clinical seizures or electroence‐
phalography (EEG) were demonstrated between the two gender [399]. Most of the reports are
for generations of childhood and young adults.
Hyperthroidism can exacerbate seizures and paroxysmal EEG abnormalities in patients with
a diagnosis of epilepsy [390,400] or focal/generalized seizures only during thyrotoxicosis in
patients without established epilepsy [401]. The mechanisms of seizure induction by thyroid
hormones are not clear, but there are some possible explanations. Thyroid hormones may
influence the activity of sodium potassium adenosine–triphosphatase, leading to severely
altered concentrations of sodium in cerebral cells. In this way thyroid hormones trigger
seizures by lowering the seizure threshold [402-405].
To confirm the diagnosis patients should be evaluated for the other causes of seizures. Any
epileptic focus or organic lesion should not be obtained with EEG, CT or MRI. Hypoglycemia,
hypoxemia, serum electrolyte imbalance, acid-base imbalance or possible central nervous
system infections should be excluded [406]. Hyperthyroidism should be confirmed by low
serum thyroid-stimulating hormone (TSH) and high concentrations of T4, T3, or both. EEG
can be used as another diagnostic tool. Severity of hyperthyroidism correlates with EEG
parameters [399]. Generally EEG abnormalities regress after a euthyroid state achieved. Thus
EEG can be used to assess response to treatment [406]. The reversibility of EEG findings
demontrates that seizures in hyperthyroidism are functional, not organic [407]. But EEG may
not be positive in all cases of hyperthyroidism with seizures, and also positive EEGs in all cases
of hyperthyroidism may not manifest clinical seizures [399].
7.5. Management
Treatment of hyperthyroidism with standard medical approaches (propylthiouracil, lugols
iodine, propanolol and dexamethasone with additional vitamin B complex) have been shown
to be effective in patients with seizures. Anti-epileptic drugs may have been useful when
standard medical approaches were not adequate to control seizures. Thus, various anti-
epileptic drugs (carbamazepine, phenytoin, sodium valproate, diazepam, or clonazepam)
were used to treat seizures in the acute phase [399,408]. HE responds to glucocorticoids,
immunosuppressive therapy and plasmapheresis which supports the autoimmune etiology.
Seizure exacerbations usually remit when patients become euthyroid with treatment [409,410].
8. Thyrotoxicosis related diabetes mellitus
Glucose metabolism disorders can be seen in thyroid disorders, especially in hyperthyroidism.
Hyperthyroid patients have a higher risk of developing diabetes mellitus. The pathogenesis
is complex and there is lack of data about prevalence and severity in the literature [411].
8.1. Epidemiology
In young individuals with an autoimmune thyroid disease (as Graves’ disease) it is common
to develop type 1 diabetes. It is due to the alteration of the immune system which leads to a
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pathological reaction against self-antigens. In fact other autoimmune diseases like celiac
disease can also occur. Thyroid auto-immunity is common in type 1 diabetic patients, with up
to 27% of them having detectable titers of anti-thyroid peroxidase antibodies [412]. A preva‐
lence study by Greco et al. confirmed the frequent association between Graves' disease and
type 1 diabetes. Graves' disease often preceded diagnosis of type 1 diabetes, particularly in
female subjects with a high age at diabetes onset [413].
In older patients, hyperthyroidism can be associated with type 2 diabetes. The pathogenetic
mechanism can be explained by insulin resistance and metabolic derangement [414]. A study
showed that patients on treatment for hyperthyroid Graves’ disease were almost twice as likely
to develop type 2 diabetes than the general population, although they were less likely to be
overweight and were less likely to have family history. This suggests an association between
Graves' disease and type 2 diabetes [415].
8.2. Genetic predisposition
Studies have been performed for HLA-DR3, HLA-DR4 CTLA-4, and PTPN22. These studies
suggest that abnormalities in antigen presentation and T cell activation might play a significant
role in the shared genetic etiology of type 1 diabetes and auto-immune thyroid disease [416].
8.3. Hyperthyroidism and glucose homeostasis
The effect of hyperthyroidism on glucose homeostasis is complex [417]. Hyperthyroidism
stimulates increased metabolism in many tissues, leading to an increased demand for glucose
[418]. Altough having insulin resistance, as long as pancreatic beta cell functions remain
normal, overt diabetes does not develop in a hyperthyroidism.
Gastric emptying and intestinal absorption
It has been suggested that rapid gastric emptying and increased rates of intestinal absorption
of glucose could be responsible for altered glucose tolerance in hyperthyroidism [419]. In
contrast to this, recent studies found that gastric emptying has been decreased [420,421] or
unchanged [422,423] in hyperthyroidism.
Liver
Hyperthyroidism can cause insulin resistance with direct and indirect effects on the liver. The
direct effect is to increase basal hepatic glucose output by promoting gluconeogenesis and
glycogenolysis [424]. A sympathetic pathway from the hypothalamic paraventricular nucleus
to the liver has been proposed as a central pathway for modulation of hepatic glucose
metabolism by thyroid hormone, which forms the indirect effect [425].
Peripheral tissues
Glucose uptake in peripheral tissues especially in the skeletal muscle have been found to be
increased in hyperthyroisdism [426-429]. This increased uptake is mainly related with an
increase in insulin-stimulated glucose oxidation rates [430-433]. Furthermore, reduced
glycogenogenesis and insulin-stimulated nonoxidative glucose elimination results with
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intracellular glucose being redirected towards glycolysis and lactate formation [428,429,434].
The release of lactate from peripheral tissues back to the liver contributes to the Cori cycle
where more hepatic glucose is being produced [434-436]. In the adipose tissue, lipolysis
increases in the fasting state. This results with an increased production of glycerol and
nonesterified fatty acids (NEFA). Increased glycerol generated by lipolysis and increased
amino acids generated by proteolysis are used for gluconeogenesis. NEFA stimulate gluco‐
neogenesis and provide substrate to other tissues such as muscle, for oxidation [437].
Cytokines
There is an interaction between thyroid hormones and adipose tissue derived cytokines. Effects
of thyroid hormones on production rates and plasma levels of these cytokines could be used
to explain mechanisms of insulin resistance in hyperthyroidism. Adipose tissue derived
cytokines are adiponectin, leptin, interleukin-6, tumor necrosis factor-α, resistin and visfatin.
There are conflicting reports about the role of these cytokines to insulin resistance in hyper‐
thyroidism [418].
Insulin and glucagon secretion
Decreased [438-442], normal, or even increased [437,443] levels of plasma insulin have been
reported in hyperthyroidism. There are conflicting reports about insulin secretion in hyper‐
thyroidism. But it is more consistent that insulin degradation increases. Hyperthyroidism
augments renal clearance of insulin [428,444,445]. Another important pathologic change
induced by long-term hyperthyroidism has been shown to be irreversible pancreatic damage
[446-448]. Secretion and metabolic clearance rates of glucagon have been found increased in
hyperthyroidism [449]. Increased levels of growth hormone and catecholamines that accom‐
pany hyperthyroidism may further contribute to insulin resistance. Interorgan communication
in hyperthyroidism are shown in Figure-6 [418].
8.4. Subclinical hyperthyroidism and glucose homeostasis
Subclinical hyperthyroidism could be endogenous and exogenous. Both of them have also
been associated with insulin resistance in some studies [450,451]. But there are conflicting
reports in the literaure about insulin resistance in exogenous subclinical hyperthyroidism.
Yavuz et  al.  have reported reduced insulin  sentivity  in  these  patients  [452,453].  In  con‐
trast  to  this  Heemstra  et  al.  have reported that  insulin  sensitivty  was not  altered [454].
According to  its  cronicity  and higher  T3 levels  endogenous subclinical  hyperthyroidism
may have a larger impact on glucose homeostasis when compared to exogenous subclini‐
cal hyperthyroidism [451].
8.5. Impact of hyperthyroidism on diabetes
In some young women with Type 1 diabetes, glucose control may fluctuate following child‐
birth due to post-partum thyroiditis, when a state of hyperthyroidism is followed by hypo‐
thyroidism. Routine screening of TSH is recommended in such patients 6-8 weeks following
delivery [455]. Thyrotoxicosis and diabetic ketoacidosis can occur simultaneously. In this
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instance the combination could be fulminant and potentially life threatening. The first goal of
treatment is to maintain electrolyte balance to avoid cardiac arrest [456].
As far as hyperthyroidism affects glucose homeostasis and causes insulin resistance,  the
patients need more insulin administration for glycemic control. Moon et al. reported a case
of hyperglycemic hyperosmolar state (HHS) associated with Graves' hyperthyroidism. HHS
rarely  associates  with  Graves’  hyperthyroidism  but  this  unusual  relation  should  be
considered [457].
9. Conclusion
In conclusion all types of thyrotoxicosis may induce severe systemic complications which may
affect morbidity, even mortality of the disease. Prompt and effective treatment of the compli‐
cations and proggresing to euthyroidism is important for the management.
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